Deficiencies PMDA published in the attachments to its GMP inspection annual reports, all in PMDA's own English text — 111 in total. FY2025 · FY2024 · FY2023.
Acceptance tests for the raw materials ● and ● for which specifications and test methods are specified in the marketing authorization of ●, and used for the manufacture of already distributed drug product were carried out using inconsistent methods from the marketing authorization as shown below. The testing facility carrying out the acceptance test communicated with the marketing authorization holder (hereinafter referred to MAH) of the product for their situation that the tests specified in the marketing authorization are difficult to carry out due to the limitation of equipment etc., but they did not communicate with the MAH regarding the situation of the test method change in the marketing authorization, and resulted in the situation of discrepant acceptance tests. (violation of paragraph 2, Article 3 of GMP Ministreal Audinance) Other discrepancies with the marketing authorizatin were noted for those raw materials and othre raw materials. Consistency with the current marketing authorization should be checked carefully, and take corrective actions if necessary. In addition, root cause investigation should be done including the reason why coordination with the MAH was insufficient, and submit detailed preventive measures. (1)The marketing authorization defines to use IR spectroscopy for the identification test of ● in accordance with the Japanese Pharmacopoeia, but the testing facility carried out the test in accordance with the United States Pharmacopoeia or the European Pharmacopoeia, due to a functional restriction of their equipment. (2) Moisture content test of ● and ● were defined to use volumetric titration method in the marketing authorization, but the testing facility used coulometric titration/vaporization method. (3)The marketing authorization specified ● detector as the detector of the instrument for quantification of impurities and for assay methos for ●. but the testing facility used ● detector.
PMDAFY2025 · No.1Quality unit oversightQuality managementSource file
As shown below, a part of manufacturing operations in the ● process of the manufacture of the inspected API including dilution of ●, and dilution of ● to be used for ● as the adjustment of atypical event (hereinafter referred to "The Dilution") were carried out by QC unit instead of manufacturing unit. (violation of items 1, 2, 3, 4 and 10 of Article 10 of GMP ministreal ordinance) (1) Though the operations of The Dilution are part of the manufacturing operation, a supervisor in the QC unit entered the detailed directions of The Dilution into LIMS system under the request from the manufacturing unit, and QC staffs carried out The Dilution under such direction. (2) Operation record of The Dilution is attached to the QC record, and the situation of this documentation did not allow responsible supervisor in the manufacturing unit who have an enough knowledge of manufacturing control to review this record. Check all the operations in your site for existence of similar deficiency, and corrective action should be taken that all the operations related to manufacturing control should be done by manufacturing unit.
PMDAFY2025 · No.2Quality unit oversightOrganizational control (organizational and managerial responsibilities)Source file
Retention period of the records relating to the inspected product including manufactuirng instruction and record and testing instruction and record is specified to the shelf life plus one year. But since the shelf life of the inspected product is 3 years, the specified retention period did not fulfill the period of at least 5 years required in item 3, paragraph 1, Article 20 of the GMP ministreal ordinance. Actually, manufacturing instruction and record and testing instruction and record of ●7 lots, ●2 lots, and ●4 lots manufactured in ● year were discarded. Retention period of records should be corrected. 【violation of item 3, paragraph 1, Article 20 of the GMP ministreal ordinance.】
PMDAFY2025 · No.3Documentation and recordsControl of document and record (including data integrity)Source file
Retention period of the records relating to manufacturing record, testing record, and training record is specified as shelf life plus one year. But since the shelf life of the inspected product is 2 years, the specified retention period did not fulfill the period required in item 3, paragraph 1, Article 20 of the GMP ministreal ordinance. As the result, manufacturing records and testing records of the inspected product manufactured in ● year and ● year, and training records carried out in● year and ● year were discarded. 【violation of item 3, paragraph 1, Article 20 of the GMP ministreal ordinance.】Written procedures should be revised to comply with the requirement of the GMP ministreal ordinance, and the period of currently retained records should be adjusted according to the revised procedure.
PMDAFY2025 · No.4Documentation and recordsControl of document and record (including data integrity)Source file
Documents and records (hereinafter referred to "Document etc.") related to the inspected biological-origin drug are required to retain for additional 5 years for training record and additional 10 years for other documents to the shelf life of the product, according to item 2, Article 30 of the GMP ministreal ordinance (hereinafter referred to "Ordinance"). But the inspected site specified the retention period of manufacturing records and testing records to be shelf life of the inspected product plus 5 years, and the period did not meet the requirement of the Ordinance. (violation of item 2, Article 30 of the Ordinance) Retention period of documents required to retain by the Ordinance should be consistent with the requirement of the Ordinance. In addition, wheter the documents related to the API used for the manufacture of the finished pharmaceutical products which were distributed to the Japanese market are discarded shorter than the period required by the Ordinance or not should be checked, and report the result.
PMDAFY2025 · No.5Documentation and recordsControl of document and record (including data integrity)Source file
Following deficiencies were identified relating to the reporting and retention of the records required for GMP control including ● report. Root cause analysis should be done and corrective actions shoud be taken for those deficiencies. Please note that those are not all inclusive list of the observed deficiencies during the current inspection, you should review all the aspect of your document control practices and establish adequate procedures and practices of record preparation, processing and keeping. (violation of paragraph 2, Article 20 of the Ordinance, except that point (4) is violation of items 1 and 2, Article 19) (1) ● reports and other essential GMP records were left on the operators desk without reviewing by second person or supervisor for more than 1 year. Multiple instances of such practices were observed. (2) Multiple records which are required to be reviewed monthly by manufacturing control manager were placed in the office room without being reviewed by the manufacturing control manager. Those are monthly report of routine inspection record of ● equipment and cleaning and other hygine control records. Those records were observed to contain multiple blank columns. Those columns include line clearance check record, cleaning and post cleaning check record. Those practices pose risks of making difficult to confirm cause relationship of any event by passage of time or risks of loosing an opportunity of necessary and timely check of abnormality or deficiency in the quality of the distributed drug product. (3) Deficient retention of record was observed in which completed routine inspection record was inadequately retained outside of the designated place. For example, routine inspection record of dust collector for ● month ● year was left in the office room, posing a risk of loosing or delaying access to the record when necessary. (4) A training plan, prepared but not yet distributed to the relevant personnel or section was left on the desk of the personnel …
PMDAFY2025 · No.6Documentation and recordsControl of document and record (including data integrity)Source file
1. The stability monitoring procedure specified that in the event of obtaining OOS test result or obtaining a data indicating a possibility of obtaining OOS result within the assigned shelf life, the manager of stability testing section in the QC unit should report such data to the manufacturing control manager and the manager of quality unit, and the manufacturing control manager or the manager of quality unit should inform the marketing authorization holder. Following events were observed in which possibilities of obtaining OOS stability test result will be obtained within the assigned shelf life in the stability monitoring report in the annual product quality review (hireinafter referred to "APQR") of the inspected product for 2024, but the manager of stability study section did not prepare report of evaluation results of stability monitoring when those results were obtained. The results of stability monitoring of the lots cited in the following (1) to (3) should be promptly reported to the marketing authorization holder and reviewing of stability monitoring data or other stability data should be carried out to take necessary actions if necessary in the event of a poosibility of obtaining OOS result within the shelf life. In addition, necessity of assigning the responsibility of carrying out objective evaluation of the effect of those incidents observed in the stability data to the QA unit should be considered. (violation of item 5, paragraph 1, and paragraph 2 of Article 11-2) (1) As the result of decrease in content value in the result of assay test of lot No. ● at the time point of ● months of the stability test of lot No. ●, the report mentioned a possibility of OOS result within the shelf life. (2) The inspected site obtained an analytical result of related substance ● in the purity test of lot ● at ● months, indicationg a possibility that the analytical result may reach to OOS within the assigned shelf life. (3) The inspected site obtained analytical …
PMDAFY2025 · No.7Quality unit oversightProduct quality reviewSource file
2. Part of testing for stability monitoring were contracted to ● due to insufficient number of personnel. Following deficiencies were observed relating to this outsourcing, and such deficiencies, including inconsistency of data by different testing period are considered to affect the reliability of data, and prevent adequate evaluation of product quality in relation to stability. (violation of Article 11-5 of the Ordinance) (1) Necessary arrangements were not made, including the communication method with the contractor, necessary technical conditions to carry out the test, how to control the collected sample during transportation, etc,, at the time of contracting the testing to ●. (2) Qualification and ability of ● to carry out the stability test of the inspected product, were not confirmed at the time of contracting, and no record was retained. Based on the above observation, following actions should be taken. (1) Review the effect of the contracted stability tests to ●, regarding the reliability of the data, taking the observation of mainor deficiency ● into consideration, and take necessary action based on such review. (2) A contract providing necessary arrangements for the test of stability monitoring should be concluded and estabiish a system by which contracted activities are controlled adequately. (3) The root causes of above deficiency (1 ) and (2) should be investigated and establish preventive measures. (4) Investigate existence of similar deficiencies in the outsourced activities other than stability monitoring, and take necessary action if any deficiency is identified,
PMDAFY2025 · No.8Material and supplier controlControl of supplyer and contractorSource file
3. Number of samples used for stability monitoring test of the inspected product was specified as ● or ●. We reviewed the sample discard record and confirmed that ● samples were used for the test of ● month time point of lot No. ●. The recorded number of sample is larger than that specified in the procedure, but the reason was unknown. On the other hand, smaller number of samples were used for the test of lot No. ● at the time point of ● months, according to the sample discard record, and the reason was also unknown. The inspected site explained that there is a possibility of mixup of the discarded lots, because the discarding records of those lots were entered in the same day. But the stability monitoring procedure provides that the details of the discarded sample should be double checked by the staff in charge of discading and second person, and actually the record was signed by those personnel. Because we noted that the sample discard record of lot No. ● was revised and the number of used sample was changed to ●, we asked the person in charge of sample discard to confirm the revised record, and the person confirmed that the record is correct. Though there was a discrepancy of the number of samples used for the test against the specified number in the procedure, the reason for the discrepancy was not recorded adequately in the above case, and such situation prevented to confirm objectively whether the test was carried out according to defined test plan and procedures. This situation pose a question whether other tests carried out in the same time period were carried out adequately without any mix-up of samples or other events. Taking the above observations into consideration, QA unit should review adequacy of laboratory practices including check of all the paper based and electronical record (LIMS) of testing instruction, testing related data, audit trails, record review results, judgement, and storage and reconciliation record of the sample for release test of …
PMDAFY2025 · No.9Stability and storageStability monitoringSource file
1. The inspected site did not submit a scientific data to demonstrate uniformity of result ● test of the dosage form of ● (hereinafter referred to "the Drug") processed by ● process, that is necessary for the process validation to assure the product quality, (violation of item 1, paragraph 1, Article 13 of the Ordinance) In particular, regarding the ● of the Drug, 2 lots of the manufactured 3 lots of performance qualification resulted in out of specification, and the review results confirmed variation of the measured values of ● among the vials in the same lot. The condition of failing to assure the uniformity of ● in the ● process directly affect the risk of product quality. Robustness of the manufacturing process of the Drug should be demonstrated by crrying out required additional validation study, or presenting any scientific data to demonstrate uniformity of ● in ●.
PMDAFY2025 · No.10Validation and qualificationValidation (general requirement of validation, validation master plan, technology transfer)Source file
2. GMP document control standard code defines that written documents should be periodically reviewed at the frequency of once every 3 years for standard codes, and once every 5 years for written procedures. But as shown in the document control list of ● month of 2025 submitted during inspection, multiple documents in each of 6 units involved in the manufacture of the Drug are not yet reviewed after the specified regular review period. More than 40% of the documents were not yet reviewed after passage of set review period in some unit, and in other case, there was a document for which deadline of review was set in 2015 is not yet reviewed at the time of inspection. Such situation indicate the status of failure of the on-going document control to assure all the prepared documents are correctly up dated. (violation of item 2, paragraph 2, Article 20 of the Ordinance) Take corrective actions promptly to resolve the situation of delayed document review for the documents for which due review period has already passed. In addition, root cause investigation should be done for the cause of long delayed review of a document, and corrective action should be implemented to prevent delay of periodical document review.
PMDAFY2025 · No.11Documentation and recordsControl of document and record (including data integrity)Source file
3. Raw materials, packaging materials and finished products which failed to meet the acceptance criteria for use in the manufacture or release for distribution (hereinafter referred to "Rejected material") are placed in the rejected material storage area attached with inconsistent labeling, caused by the result of absence of labeling and related procedures for Rejected materials. Materials registered in manufacturing execution system (hereinafter referred to as "MES") and materials de-registered from MES system for discarding were placed in this area, but those stored materials were not labeled nor placed in the separated area for different status in MES. It is difficult to identify the status of the stored material under this condition, and that pose a risk of using rejected material by mistake or intentionally. Further review of the control status of the above materials and procedures revealed absence of a procedure for recording rejected material and reporting to the Authorized Person based on such record. Under such situation, those records and documents were not prepared and the status of handling and recording of rejected materials were not under control. In addition, no person in charge of controling disposition of rejected material is appointed. (violation of paragraph 2, Article 17 of the Ordinance) Procedures for controling rejected materials should be established, requiring documentation of disposition record of rejected materials, and report it to the organizational unit in charge of quality assurance and to the Authorized Person in writing. In addition, detailed procedures for controling rejected materials should be established including labeling, storage, registration in MES, and disposition. Along with such procedures, corrective actions should be taken regarding personnel responsibilitis related to those observed deficiencies, by appointig a personnel in charge of disposition of rejected materials among the personnel who knows the handling of …
PMDAFY2025 · No.12Other quality systemControl of rejected material.Source file
1. Following deficiencies were observed regarding the change control for ●. One of the root causes for those deficiencies is unwareness of the revision of the Japanese GMP ordinance (the Ordinance) revised in 2021. As the result, discrepancies between the marketing authorization of ● and the actural manufacturing operations were observed including unimplemented in-process control test and changed batch scale, and the site failed to control consistency of the manufacturing procedures with the marketing authorization. (violation of item 3, paragraph 1, Article 5 and Article 14 of the Ordinance) (1) Though the change control procedure was implemented for ● API for ● market and ● market for the purpose of increasing the batch scale of step ● and step ●, this change control was not implemented to the API for Japan. (2) The change control procedure of this manufacturing site define that QA should conduct analysis of impact of planned change to the product quality and to the marketing authorization, and if such change is considered to affect the product quality or marketing authorization, such plan should be informed to the customer before implementation, and implemented after obtaining confirmation of the customer. But we observed multiple instances of changes uninformed to the customer, and which are thought to have impact to the drug master file (hereinafter referred to MF). (3) The procedure of this manufacturing site define that changes having an impact to the product quality or marketing authorization should be informed to the customer in accordance with the quality agreement with the cutomer. But there was no provision of informing implemented changes to the customer, in the quality agreement. As the result, there was no organizational responsibility to inform changes to customers. Actually, we observed multiple instances of changes uninformed to the customer, and which are thought to have impact to the MF. Taking the above observations into consideration …
PMDAFY2025 · No.13Regulatory reporting and change controlChange controlSource file
2. The procedure for release of product defined that the status of change control, deviation handling, OOS investigation, and process validation (hereinafter referred to as PV) should be confirmed then decision for release of the batch should be made. But a batch of API manufactured using an intermediate manufactured as the 1st batch of the prospective PV batches to validate changes of batch scale of Step ● of the manufacture of ● and the manufacturing line was distributed before completion of the PV. Incomplete PV and change control were not confirmed at the time of batch release. Adequacy of the product quality released before completion of PV should be confirmed. And investigation of the deviation that the batch release was not done in accordance with the procedure should be carried out, and root cause investigation and preventive action should be done. In addition, existence of similar event should be checked for the other inspected product ● and ●, and take the same action if such event was observed for those products. (violation of paragraph 1, Article 12 of the Ordinance)
PMDAFY2025 · No.14Quality unit oversightRelease of productSource file
Multiple defects were observed in multiple records prepared from ● year to ● year, including unfilled fields and unfilled judgement results. For example, "● reagent preparation record ・use record ●" for lot ● and ●, have a column recording confirmation of loading specified amount of reagent by the person in charge of the loading, but there was no entry in that column, and this failure was not detected nor corrected, and there was "Approval of use" by ● manager in the record. The inspected site noticed those failure in this record, and opened deviation (●) on ● day ● month ●year, and carried out unplanned self inspection to confirm reliability of other records. Detailed progress of the self inspection was not clear, at the time of current inspection, because the root cause investigation and the unplanned self inspection were on-going. Under such situation, root cause of the deviation was not clarified nor the corrective and preventive action were implemented. In addition, interim measures to ensure reliability of the records to be prepared until the corrective and preventive actions are implemented, were not implemented. The situation of the site did not ensure reliability of records. (violation of Item 2 and 4, paragraph 2, Article 20 of the Ordinance. ) The inspected site should fix schedule of each action including due date of corrective and preventive action, root cause investigation, unplanned self inspection, and actions to be taken as part of the corrective and preventive actions, and root cause should be investigated without delay and implement corrective and preventive actions. In addition, interim measures necessary to ensure the reliability of records should be taken to assure the quality of the currently manufacturing products. Actions taken for those failures, and results of investigation of root cause and results of unplanned self inspection, and progress report of those actions to be taken as the corrective and preventive actions should be submitted …
PMDAFY2025 · No.15Deviation, CAPA, and investigationDeviation managementSource file
There were around ●●● events of deviations for which the deviation procedure requires to decide necessity of corrective action and preventive action (hereinafter referred to CAPA) among the deviation events ocurred in 2025. But ●● events were remained without implementing CAPAs within the defined time period in the procedure, and the longest delay was ●●● days. Among those deviations, there was a case of detecting ● cfu of microorganisms in the surface monitoring in the ● located in Grade A area, indicating insufficient decontamination of the area. As shown in this case, there were deviation events which will possibly affect the product quality. 【violation of (a), item 2, Article 17 of GCTP ministerial ordinance】 Necessity of CAPA should be promptly decided for the events for which CAPA necessity is not decided yet, and required CAPA should be implemented. In addition, the reason why the decision of CAPA necessity and CAPA implementation were delayed should make clear and take adequate preventive action.
PMDAFY2025 · No.16Deviation, CAPA, and investigationDeviation managementSource file
1. Recurring deviations similar to following event (1), and possibly recurring events (2) and (3) were observed, due to insufficient root cause analysis in deviation management, and those resulted in lack of effective corrective action and preventive action (hereinafter referred to "CAPA").【violation of item 2, paragraph 1, Article 15 of the Ordinance】 Adequate deviation management system should be in place, including review of existing deviation procedure, to ensure adequate root cause investigation and implementation of effective CAPA addressing the root cause. (1) The record of (●) deviation in which unqualified operator carried out ● operation concluded that ● manager instructed to do the operation without checking the list of qualified operator, and the instructed operator did not aware his or her own qualification status. As the preventive action, the site introduced a procedure to inform the list of qualified operator when the list is up dated. But they did not examine the root cause of failure to check the list of qualified operator at the time of instruction of operation. This event was a recurrent deviation, and as the corrective action for the previous event, the site set a easy to find place for storage of the list of qualified operator for improved access to the involved personnel. But failure to check the list of qualified operator is considered to be major root cause and it is considered that informing up dated list of qualified operator to all the involved personnel alone is insufficient as the preventive action. (2) Investigation of the deviation (●) in which a material not registered in the material list was brought into the warehouse and used for the manufacture revealed that the material was received without checking the material list and the received material was registered in the inventory management system even the material was not registered in the material list. For the latter of those two failures, corrective action was implemented to …
PMDAFY2025 · No.17Deviation, CAPA, and investigationDeviation managementSource file
2. The procedure for reviewing test record defined to confirm absence of vacant entry field, absence of discrepancy of entered records. When we reviewed the test record of already distributed ● (lot No.:●), multiple defects indicating inadeuate entry, check and review of record was observed including no signature in work instruction, missing date of work, mistake in issue date for 1year, even though the record was reviewed multiple times by quality control manager and person in chage of release. Effectiveness of record review procedure and its implementation is considered to be inadequate, and integrity of record was not assured. 【violation of paragraph 2, Article 20 of thee Ordinance】
PMDAFY2025 · No.18Documentation and recordsControl of document and record (including data integrity)Source file
The release procedure of this site permit distribution of the inspected API product from this site before completion of necessary steps of batch release (under quarantine), and actually the API was distributed from this site before completion of batch record review.【violation of item 4, Article 12 of the Ordinance】 Release procedure should be revised to prevent distribution of the product under incomplete steps for batch release.
PMDAFY2025 · No.19Quality unit oversightBatch releaseSource file
Conditional Release was permitted in those manufacturing sites. This is a provision to permit distribution of API and intermediate product from the site, after confirming critical test results of the release test and in-process test, on the condition of obtaining approval for other records until those products are distributed to the market. In addition, the procedure permits review of deviation record classified as Major or minor grade, change control record and OOS record after distributing the product. Among already released drugs, Conditional Release was actually applied to multiple lots of the products manufactured for the Japanese market.【violation of paragraph 4, Article 12 of the Ordinance】 Procedure for batch release decision should be up dated to make the decision after evaluating whether manufacturing operation and laboratory operation of each lot were adequately carried out.
PMDAFY2025 · No.20Quality unit oversightBatch releaseSource file
1. Because the shelf life of the inspected product is ● hours, the marketing authorization of the product defines that the product will be shipped from the manufacturing site before the result of sterility test become available. But the site did not establish a procedure defining acthions to be taken when out of specification sterility test resuld is obtained after shipping the product from the site.【violation of Article 13 of the GCTP ministreal ordinance】 Actions to be taken when out of specification test result is obtained after shipping the inspectd product should be defined in advence in the written procedure.
PMDAFY2025 · No.21Quality unit oversightBatch releaseSource file
2. Though the inspected site carried out prospective process validation for key intermediate, prospective process validation or verification for final product ● was not carried out. 【violation of Article 14 of the GCTP ministreal ordinance】 Facilities and equipment, procedures, processes, and other methods of manufacturing control and quality control related to the manufacturing process of ● should be validated and those activities should be documented.
PMDAFY2025 · No.22Process validationValidation (process)Source file
3. Following in-process control tests were added to the marketing authorization application during the process of examination of the application, but we observed that the inspected site was not ready to carry out those tests. 【violation of paragraph 2, Article 12 of the GCTP ministreal ordinance】 Ncecessary actions should be taken to enable to carry out following in-process control tests. (1) Written test procedure and record form were not established for in-process test ● for ● manufacturing process. (2) The site did not have necessary testing equipment for in-process test ● for ● manufacturing process, and written test procedure and record form were not established.
PMDAFY2025 · No.23Laboratory and QC controlsLaboratory procedures・records (including Data Integrity)Source file
4. Because the product ● do not constitute a lot, the inspected site defined the procedure for retain sample to retain the sample of a key intermediate for the shelf life of the product manufactured from the key intermediate plus 10 years. The GCTP ministreal ordinance and its Article by article commentary define to retain eaci lot of biologial origin raw material of regenerative medicinal product, with the amount of not less than twice of necessary amout for the specified quality control test (adequate amount to carry out sterilit test, endotoxin test and mycoplasma test), but the inspected site did not retain necessary amount of sample of the key intermediate for sterility test though they retain not less than twice of the necessary amount for other tests than sterility test. 【violation of Article 12 of the GCTP ministreal ordinance】 To prepare for a future situation of arising a necessity of confirming product quality in the event of detecting some quality defect for the distributed regenerative medicinal product, necessary amount of retain sample to carry out sterility test adequately should be retained.
PMDAFY2025 · No.24Laboratory and QC controlsRetain sample, retention sampleSource file
1. The inspected site manufactured multiple non pharmaceutical industrial products, and trial manufacture of active pharmaceutical ingredients contracted from other manufacturer(s) to be used for verification of purification or milling (hereinafter referred to Industrial Products). Though those Industrial Products are not intended to be used for human body, the inspected site did not show the justification of sharing the work room with Industrial Products nor clarify that they don't handle any material of easy to form dust, or having hypersensitivity with trace amount, and that the materials do not have high pharmacological activity nor high toxicity. In addition, they didn't take cross contamination provention measures based on the scientific data by pharmacological and toxicological evaluation of the materials to share the work room and manufacturing equipment. Following actions should be taken from the viewpoint of prevention of cross-contamination.(violation of Article 8-2 and paragraph 2, Article 9 of the Ordinance) (1) Identify the product and lot number which have a possibility of cross contamination with Industrial Products, and confirm that the lot is actually cross contaminated using retain sample. Report the result promptly, and when the fact of cross contamination is confirmed, it should be informed to the marketing authorization holder of the product, and take necessary action. (2) Justification of sharing the work room with Industrial Products until now should be checked, and report the result promptly. Minimum of the following points should be included for the justification. If the result of such check indicate there is no justification, work room should not be shared with Industrial Products until such sharing is justified, and promptly report it to the marketing authorization holder and take necessary action. 1) Confirm that no material of easy to form dust, or having hypersensitivity with trace amount is handled in the manufacturing of Industrial …
PMDAFY2025 · No.25Contamination controlContamination control systemSource file
2. An event listed in the list of deficiencies as major deficiency 1, was observed related to the revised provision in the promulgated ministreal ordinance dated 28th of April 2021, revising a part of "Ministerial Order on the Standard of Manufacturing Control and Quality Control for Pharmaceuticals and Quasi-Pharmaceuticals" (Ministreal order No. 90 of 2021). Part of the root cause of this event is due to the failure of the authorized person to manage adequate and smooth conduct of manufacturing and quality control operations due to inadequate staffing of the personnel who knows the content of the revision of the ministreal ordinance. Organization of the manufacturing site should be improved to enable adequate and smooth conduct of manufacturing and quality control operations. (violation of Article 5 and Article 6 of the Ordinance)
PMDAFY2025 · No.26Quality unit oversightOrganizational control (organizational and managerial responsibilities)Source file
3. The organizational structure of the inspected site consisted that the manufacturing unit and quality unit are placed under the supervision of the authorized person for drug manufacture, and there are quality assurance department in charge of quality assurance operations and quality control department in charge of test and inspection operations in the quality unit. But among the control items of the raw materials described in the drug master file, functional test items and conductivity test for ordinary water, deionized water and mother liquor were carried out by the manufacturing unit. In addition, the quality unit did not make judgement of such test results, and as the result, raw materials witout judgement of test result were used for the manufacture. Raw materials tested and released by the quality unit should be used for the manufacture. (violation of paragraph 1, Article 11 of the Ordinance)
PMDAFY2025 · No.27Quality unit oversightOrganizational control (organizational and managerial responsibilities)Source file
4. The inspected site shared manufacturing equipment for the manufacture of multiple active pharmaceutical ingredients. But the site did not carry out cleaning validation for some of the active pharmaceutical ingredients (●, ● and ●) because of absence of quantitative analytical method for the ingredient which is the indicator for residue of the active substance(hereinafter referred to "Indicator ingredient" in the facilities and equipment, and they did not demonstrate that the residual ingredient is removed from the equipment by appropriate cleaning procedure. in addition, the cleaning procedure did not allow adequate assessment that the cleaning method provide expected cleaning efficacy. Following actions should be taken for prevention of cross contamination. (violation of Article 8-2, itemi1, paragraph 1, Article 9, and Article 13 of the Ordinance) (1) Identify possibly cross contaminated products and lots, and confirm existence of cross contamination using retain sample or other material. Report the results of such confirmation promptly. If existence of cross contamination is confirmed by such investigation, inform the result to the marketing authorization holder of the product, and take necessary corrective actions. (2) Procedure for cleaning validation should be up dated taking the following points into consideration. 1) Validated analytical method for Indicator ingredient should be established to assure sufficient analysis of residues after cleaning. 2) Residual amount should be evaluated taking the recovery rate of the residues against product contact materials in the equipment into consideration, for the sampling by swabbing, rinsing or by other means. 3) If the manufacturing is done by campaign basis, cleaning valiation should be done incorporating the worst case conditions, including maximum number of batches in one campaign, maximum time after cleaning to use, etc. 4) Limit for the control of residue of individual Indicator ingredient should be based on …
PMDAFY2025 · No.28Cleaning validationCleaning and cleaning validationSource file
5. Records of milling process and shieving process were missing in the manufacturing instruction and record form of the inspected product (Lot No. ●). The batch manufacturing instruction and record form should be revised to add the records of those processes so that those processes were carried out in accordance with the manufacturinjg instruction. In addition, confirm record of other lots of the same product and record of other products whether all the works carried out for the manufacture were adequately recorded, and if there is similar inadequacy, take the same action as above. (violation of Article 10-4 of the Ordinance)
PMDAFY2025 · No.29Documentation and recordsManufacturing instruction ・ record (including data integrity)Source file
Raw materials issued from warehouse to manufacturing building were loaded to a carrying cart in a raw material transient storage room, and transferred to other area including weighing room. We observed multiple carrying carts contaminated by raw material and other material. For example, a cart in the raw material transient storage room carrying a residue of ● after weighing, had white powder on the upper surface and on the hand rail. Cleaning procedure of carrying cart is not defined and there is no cleaning record. Because those carts are taken into weighing room, a possibility of contamination of other raw material when the container of the material is opened for weighing is not denied. In addition, because positive air pressure is set to the corridor ageinst connected work rooms, there is a possibility of scattering of the attached powder on the carrying cart to the connected work rooms. Further to those conditions, other failures in cross contamination prevention measure were observed as listed in the other deficiency ●, including insufficient cleaning and verification of cleanliness for the weighing room and equipment in the weighing room. (violation of Article 8-2 of the Ordinance) Corrective actions for cross contamination prevention should be taken after checking existence of similar defects.
PMDAFY2025 · No.30Contamination controlPrevention of foreign matter, contamination ・ mix-upSource file
Following deficiencies related to aseptic operations were observed in the air flow visualization study (hereinafter referred to "Smoke test") simulating the manufacturing operation of ●. Events of positive results in viable air sampiing in Grade A area were recorded, and from those events and observations, adequacy of prevention of microbiological contamination of the products was not confirmed. (violation of Article 24-3 of the Ordinance) Following action should be taken. In addition, taking the fact of detecting air borne microorganisms in Grade A, risk assessment should be done from the perspective of product contamination, and corrective action should be taken to maintain Grade A cleanliness by reducing operator's manual interventions, if necessary. In addition, if those deficiencies are also observed in other sterile drug products including ●, corrective action should be taken if necessary. (1) Following operations ① and ② were simulated in the smoke test to verify the air flow, but the observed air flow paused a risk of microviological and other contamination risk, because the air contacted to the operator passed through vials. ① Manual vial stacking operation in Grade A area after half stoppering of filled vials with rubber stopper. ② Manual loading of filled and half stoppererd vials into lyophylizer in Grade A area. Risk asessment should be done from the view point of product contamination risk, and corrective action should be taken by reviewing the operating procedure and method for preventing the influx of air flow contacted to the operator. After implementation of corrective action, repeat the smoke test to confirm the result of corrective action. (2) The inspected site explained that the stacked vials into trays are transferred to vial transfer lane connecting to the lyophylizer manually in Grade A area. But this operation was not covered by the smoke test. Additional smoke test for the related operations should be done to evaluate existence of product …
PMDAFY2025 · No.31Contamination controlPrevention of foreign matter, contamination ・ mix-upSource file
The inspected site explained that they are planning to obtain marketing authorization with the result of the velification of manufacturing process of the product for 3 lots of the inspected product manufactured during the manufacture of investigational product, as the data for process validation (hereinafter refferred to "PV"), due to the reason that the PV planned to carry out at 10 taimes larger manufacturing scale of the manufacture of investigational product is not yet completed. But the plotocol of the verification do not clearly state acceptance criteria to be set taking the factors having an influence to the product quality. In addition, the valification study did not contain re-granulation process of ● µm opening sieve passed fraction that is described in the marketing authorization application document, and the evaluation result of this process was not included.(violation of Article 13-1 of the Ordinance) Taking the above points into consideration, the inspected site should verify through PV studies that the product having the required quality is obtained under the previously planned manufacturing conditions and acceptance criteria. For the planning of PV studies, risk assessment of the manufacturing process should be done, and take into consideration of the result. And following items should be reported when they become available. (1) PV overall schedule (2) PV protocol (3) PV report (4) Critical deviations or other events occured during PV
PMDAFY2025 · No.32Process validationValidation (process)Source file
1. Though the inspected site needed corrective action for the manufacturing control of the filling process of the inspected product, because the process validation studies (hereinafter referred to "PV") of the inspected product revealed results that do not meet the previously set criteria and an issue of intra lot uniformity was suggested, we could not confirm that the site took neccesary action. (violation of paragraph 2, Article 13 of the Ordinance) Root cause of the following (1) to (4) should be investigated and necessary corrective action should be taken. (1) Filling amount in the filling process is in-line checked at once every ● strokes of filling, and the acceptance criteria of the filling amount for PV was ●~● g. Though multiple results failing to meet the acceptance criteria occured, the site judged the process as acceptable, by segregating a range of filled product when the in-line check result of the filling amount exceeded the acceptance criteria. The judgement by segregating a portion of failed product by a spot test is not considered as adequate evaluation of accuracy of filling amount against the judgement criteria of actual range of filling amount of each unit container, and the evaluation is considered as inadequate because segragation of any failed portion of a lot makes the lot acceptable. (2) For confirmation of uniformity of a lot, samples were taken at initial, middle, and last of the filling process and the samples were analysed. Among the test items of such sample, test results of content of ● increased from the initial to end of filling process for all lots. In the 3rd lot of PV, result of initial of filling was ● µg/mL and the result at the end of filling process was ● µg/mL. But the reason for this is unknown and the basis that those results do not affect the uniformity of lot nor the robustness of the process were shown by the site. (3) The inspected site conducted circulatory filling of the drug solution of ● which has marketing …
PMDAFY2025 · No.33Process validationValidation (process)Source file
2. The judgement criteria for the AQL test carried out to the units passed the inspection by automatic inspection machine in the inspection process of the inspected product is defined to be "no easily detectable insoluble foreign matter", "critical defect should be less than 1 unit, major defect should be not more than ● units, minor defect should be not more than ● units," and deviation procedure should be applied if the result do not meet those criteria. Deviation procedure was applied to an event of critical defect found in the 3rd lot of PV, in which foreign matter was observed in one unit of liquid product during AQL test of automatic inspection passed units. The detected foreign matter was identified to be glass particle derived from broken glass cyringe and the size was 389 µm×219 µm. But the inspected site judged the foreign matter as "not easily detectable" only because it can be viewed as 100 µm×200 µm depending on the angle of viewing, even though it was visually detected. In addition, they handled this event as "major defect" instead of "critical defect", and judged to be meet the criteria, and necessary actions including confirmation of abcense of foreign matter contamination for other products were not taken. (violation of item 2, paragraph 1, Article 15 of the Ordinance) Impact analysis for the above lot should be done and actions should be taken to prevent distribution of foreign matter contaminated product by implementing actions to adequately reject foreign matter contaminated units.
PMDAFY2025 · No.34Deviation, CAPA, and investigationDeviation managementSource file
Technical transfer of the test method for ● was not completed at the time of our on-site inspection, and it was not verified yet that the test and inspection method for ● is capable of consistently giving the expected results. (violation of paragraph 1-3, Article 8 of the Orinance) After completion of technical transfer, results of this validation should be promptly submitted. In addition, written testing procedure and master testing instruction and record should be prepared and submitted.
PMDAFY2025 · No.35Validation and qualificationValidation (analytical method)Source file
Following deficiencies were observed in the quality control records in which contemporaneousness and integrity of data are not guaranteed. (violation of paragraph 1-2 and 1-3, Article11, and paragraph 2. Article 20 of the Ordinance) (1)-1. During the test of ● capsul ●mg (lot No.: ●, ●, ●, and ●), result of quantitative test near to the lowerlimit of the specification was obtained, and retest was carried out by the instruction of a manager who checks test results, without following the OOS/OOT procedure. In addition, reconciliation of the test sample of the product used for the retest was not retained. During the current for cause inspection, we checked the amount of the sample, recorded as used for the test, unused sample, sample for retain, other remained sample, and compared total of those sample against the initially sampled amount. As the result, there were discrepancies of 4 to 44 samples. Though the procedure for issuing test record form defines that the person in charge of controlling the record issues the record form by filling the column of lot number and the name of the issued person, those columuns in the record forms before retest were vacant. (1)-2. QC test sample of ● capsul ●μg (lot No.:●) was used for on the job training of QC personnel as the use for other purpose, and content uniformity test was carried out. One capsule of the sample was used for this test and this use record was recorded in the reconciliation document of the product test sample. But the manager who checks test results considered that the use of the product test sample for on the job training is inadequate, and instructed by attaching a sticky note to revise the use record of the capsule, and the record was replaced and revised. (1)-3. The analyst carried out the ● test of the inprocess product ● (lot No.: ●) copied the completed test record for the purpose of using the copy as a reference for the test to be carried out in the future. When a record is copied, the procedure …
PMDAFY2025 · No.36Laboratory and QC controlsSampling, control of sampleSource file
2. Though the executive management mention lack of human resources in the report of management review, and continuously took actions to retain personnel, those actions did not result in resolution of lack of resources. Actually deficiencies such as the major deficiency 1 in the list of deficiencies became apparent. Executive management did not understand those actual situation, and did not take necessary actions sufficiently. (violation of item 4 of Article 3-3, and paragraph 2 and paragraph 3, Article 6 of the Ordinance) Deficiencies observed during the current for-cause inspection are considered to result in fraud or hiding inconvenient information, and it is not denyed that persistence of the current situation could result in negative impact to the product quality. To assure addequate conduct of quality control activities, root cause of this deficiency should be investigated under the leader ship of executive management responsible for regulatory affairs, and effective and necessary immediate actions which can be handled within this manufacturing site should be taken including review of staffing, review of the amount of tasks of each manager.
PMDAFY2025 · No.37Quality unit oversightQuality managementSource file
Following deficiencies relating to the control of raw data of the results of test and inspection were confirmed. (violation of item 2, paragraph 2, Article 12 of the GCTP ministreal ordinance) Root cause investigation and impact analysis should be done for each of those deficiencies. To ensure sufficient reliability of record, and taking the situation of missing record as described in the other deficiencies 10 and 16 in the list of deficiencies, current procedures for recording and control of data should be reviewed.. (1) A photograph taken by ● was attached to the test record related to the identification test of ● recorded on ● day ● month ●year. When we asked to show electronic data of that photograph, there was no electronic data dated ● day ● month ●year in the relevant storage folder, and an electric data of a photograph of the same lot but the date of this photograph was different. The inspected site could not explain the reason, and reliability of the content of that test record could not be confirmed. (2) When we requested to show electronic data for ● of the identification test ●, the data did not exist in the relevant folder, and could not confirm existence of this data.
PMDAFY2025 · No.38Data integrityReliability and storage of raw dataSource file
Stability monitoring procedure defines that the judgement of the test result of strength of ● is done by the result of ● test as salvage test, when the initial test failed. Though inadequacy of conducting salvage test was pointed out during the previous PMDA inspection, the inspected site did not revise the procedure. As mentioned in the column related to OOS events, a case of judgement to meet the requirement by salvage test was observed in the stability monitoring program of ● year. Written procedure for stability monitoring should be revised by adequately correcting the procedure to be able to assure that the product strength is kept throughout the shelf life of the product.
PMDAFY2025 · No.39Stability and storageStability monitoringSource file
Following two events were observed related to strength test in the stability monitoring of ●. As the result of reviewing record of strength test in the stability monitoring record from ● year onward, result of ● became lower than the specification before the shelf life of ● months, and in some year, there was a case in which the result of ● test was lower than the specification at the time point of ● months. But the inspected site did not take any action of OOS for those lots failed to meet the specification of ● test in the stability monitoring, because they deemed that the strength of a lot is satisfactory when both of ● test and ● test were carried out and the result of one of them meet the specification. For this reason, they did not conduct root cause investigation for those events and judged there is no problem in the stability of the product. The situation of the inspected site did not considered that they are possible to evaluate the impact of those events to the quality of the inspected drug product. (violation of item 8, paragraph 1, Article 11, item4, paragraph 1 Article 11-2, and paragraph2, Article11-2 of the Ordinance) As a ●, ● of the inspected product correspond to strength, and the value of it is the basis for determining the filling amount of the finished product. To guarantee the value of ● throughout the shelf life of the finished product is critical for the quality control of the product. For this reason, the provision of current procedure "there is no problem in the strength of the product if either ● test or ●test meet the specification" should be revised. In addition, if ● test in the stability monitoring failed or there is a possibility of fail, take necessary actions taking the possibility of deterioration of the product quality into consideration. In addition, taking into consideration of the events of falling the result of ● below the specification within the shelf life of the product during the stability monitoring, corrective and …
PMDAFY2025 · No.40Stability and storageStability monitoringSource file
The inspected manufacturing site did not establish a procedure to take necessary actions when there is a possibility of obtaining OOS test result of a product in the stability monitoring, including informing it and providing information necessary for deciding product recall to the marketing authorization holder of the product (hereinafter referred to "MAH"). In addition, more than 10 cases of events for which adequate actions were not taken even though OOS stability test result may be obtained during the period of about ● years from ●month ● year. 【violation of item 4, paragraph 1, Article 11-2, and paragraph 2, Article 11】 - OOT assay test result was obtained at the ●month time point of the stability monitoring of ●, and the inspected site estimated that the assay result will become OOS at the time point of ● months within the shelf life of the product based on the result of regression analysis. But the site did not inform this to the MAH. In addition, though the QA unit instructed the QC unit to pay attention to the result when the monitoring result of ● months time point become available, the QC unit did not carry out regression analysis and the manager of quality control did not confirm that the lot maintain required quality throughout the assigned shelf life. - OOT assay test result was obtained at the ●month time point of the stability monitoring of ●, but similar to the above situation, the site did not inform this event to the MAH nor conduct adequate evaluation at that time. Following corrective actions should be taken against the above deficiencies. (1) Procedure for stability monitoring should be adequately up dated. (2) Root cause of the above deficiencies should be investigated and preventive actions should be implemented. (3) Review all the results of the on-going stability monitoring. If the result of such review indicate a possibility of failing to meet the specification of the product throughout the shelf life of the product, inform the MAH and …
PMDAFY2025 · No.41Stability and storageStability monitoringSource file
The review report of the partical change application for change of ●, submitted in ●month ● year related to ● of ● (hereinafter referred to "The partial change application") describe the basis for setting dosage and administration as "●". Actually during the review of The partical change application ● reported to PMDA Office of ● that the ● of the manufactured lots at that time (● lots) were from ● to ●, and equivalent to ●. And regarding the stability of the product, they reported that the equivalent level of ● as ● was maintained during storage as demonstrated by the value of from ● to ● at the time point of ● months in the long term stability test of the product manufactured in ● year. On the other hand, as shown below, the result of stability monitoring from ● year to 2025 submitted during the current inspection revealed a lot for which the value of ● went down to significantly lower than ● before expiration of the shelf life (● months). ・At the start of storage: from ● to ● ・After ● months storage: from ● to ● ・After ● months storage: from ● to ● Though those stability monitoring results suggest that the quality required as ● is not satisfied, necessary corrective actions including impact acessment to the quality of this drug product were not taken. (violation of item 4, paragraph 1, Article 11-2 of the Ordinance) Root cause of the tendency of decreased value of ● for the lots manufactured from ● year to 2025, compared to ● of the lots manufactured before ● year should be investigated and required corrective and preventive actions should be taken. In addition, consult with Review Office ● immediately regarding ● including the item indicated in ●.
PMDAFY2025 · No.42Stability and storageStability monitoringSource file
From ● year to ● year this manfacturing site has been manufactured ● using an API intermediate procured from a manufacturing site that is not defined in the drug master file (hierinafter referred to MF, and the manufacturing site is referred to unapproved manufacturing site), and exported ● lots to Japan. when we reviewed the cause of deviation from MF, we found that the inspected site did not recognize the content of the description of MF until the inspector pointed out during the current onsite inspection, and the site did not adequately control the source of raw material. (This is a violation of Article 7 Paragraph 1 of GMP ministreal ordinance.) In additon, when the inspected site started procurement of this raw material in ● year, this site did not inform this to their customer. We confirmed that the inspected site already stopped purchasing from the unapproved manufacturing site as of the date of our inspection. Taking such situation into consideration, root cause of the failure of adequate control of the conditions described in MF should be investigatrd, and adequate preventive action should be implemented.
PMDAFY2024 · No.1Quality unit oversightQuality Management(Management review, Quality policy)Source file
In addition to more than one item of discrepancies between the actual situation of the site and the registered information in the marketing authorization dossier, the inspected manufcturing site did not establish systems to conduct manufacturing control and quality control in accordance with the Japanese marketing authorization. (Violation of Article 3, paragraph 2 of GMP ministerial ordinance.) And though they have a procedure that any issue related to change control or deviation handling which is judged by their quality assurance unit (hereinafter referred to as QA) that the issue have a possibility of requiring regulatory submission, should be informed to their customer relevant to the issue, QA did not aware the content of the marketing authorization, and there is a possiblity that those issues are not informed to their customer. The inspected site should promptly obtain the necessary content of marketing authorization from the marketing authorization holder, and check the consistency between marketion authorization and MF, and actual situation in the manufacturing site, take necessary actions to assure consistency, and establish a system to prevent additional discrepancies. (1) Identification test ● of ● described in the marketing authorization dossier was not carried out in the in-process control and final product specification test, because the information of relevant part of marketing authorization dossier was not supplied from the marketing authorization holder. (2) Regulatory affairs unit of the manufacturer had copy of MF of API ● and its English translation, but discrepancies were noted between the actual practices of the manufacturing site and MF as shown below. Though there is a possibillity that the regulatory affairs unit recognized those discrepancies in the past, there is no record to confirm this, and the manufacturer did not take any action to resolve the discrepancies at the time of on-site inspection. 1) The MF of ● defines the maximum hold …
PMDAFY2024 · No.2Quality unit oversightQuality Management(Management review, Quality policy)Source file
1. There is no system to confirm that the manufacturing processes and quality control tests are carried out consistent with the contents of the drug master file (hereinafter referred to as MF), and as the result, following discrepancies were observed. (violation of Article 3 paragraph 2 of GMP ministerial ordinance) The minor change of the MF of the inspected product "●" ( hereinafter referred to as this product) in ● year added three test items of identification, moisture content, and related substances in the in-process control of the intermediate of this product, but the inspected site did not carried out the test for related substance. Root cause of this discrepancy should be promptly investigated and necessary actions should be taken including carring out full tests according to the revised testing procedures after the change of MF. In addition, at least 4 events of discrepancies between the content of MF and the actual practices in this site are observed other than the above event. To avoide discrepancies between the content of MF and actual practices, the content of MF should be correctly understood and manufacturing practices should be adequately controlled based on such understanding.
PMDAFY2024 · No.3Quality unit oversightQuality Management(Management review, Quality policy)Source file
2. Following deficiencies were observed regarding change control. Impact of the planned change to the product quality and marketing authorization should be evaluated, and the changes possibly have an impact to the product quality or manufacturing authorization as the result of impact analysis should be informed to the customer or other necessary parties to obtain their confirmation. And the systems should be improved to take necessary actions timely and without fail, including revision of related documents, training, validations. (Violation of Article 14, paragraph 1 of GMP ministerial ordinance) (1) There was no provision of evaluating an impact to the marketing authorization, in the change control procedure of the manufacturing site. In addition, there was no provision of revision of the affected documents, nor the provision of confirming completion of necessary training of the imvolved personnel in the change. (2) Following events of non-compliance to the change control procedure were observed: 1) The change control procedure defines to follow the provisions of quality agreement if such agreement is concluded. And the quality agreement concluded among the four parties of ● (hereinafter referred to as this site) ● (hereinafter referred to as API manufacturing site) , in-country care taker of MF, and marketing authorization holder defines that all the changes to be implemented in this site should be informed to the API manufacturing site. But there was no record of informing the change of loading amount of ● from ● kg to ● kg in the ● process in the manufacture of the inspected product to the API manufacturing site, and the marketing authorization holder and in-country caretaker of the MF did not receive the information. As the result, the actual manufacturing operation and the content of MF became discrepant. 2) The change control procedure defines that a change of test method is classified as clitical change, and the procedure requires to evaluate impact to the …
PMDAFY2024 · No.4Regulatory reporting and change controlChange controlSource file
1. The description of the manufacturing procedure in the inspected manufacturing site in the marketing authorization dossier defines that the inspected site should carry out acceptance test of API. In accordance with this provision, the inspected site have to assure the specifications of API ● specified in the addendom of the marketing authorization. But as the result of changing the test method of related substance ● of the API without taking necessary regulatory procedures, a discrepancy between the marketing authorization and the actual manufacturing operation (hereinafter referred to as discrepancy) was introduced. (Violation of Article 3, paragraph 2 of GMP ministerial ordinance) Adequate action should be taken as follows: (1) Check the consistency between the marketing authorization and the actural manufacturing practices for existence of additional discrepancies. After completion of such check, report all the identified discrepancies including the above issues, along with the situation of occurence of such discrepancies. (2) Investigate the root cause of the identified discrepancies in the above (1) and establish preventive actions. (3) Investigate the root cause of the non compliance of the marketing authorizatin by previous over looking of the identified discrepancies in the above (1) and establish preventive actions.
PMDAFY2024 · No.5Quality unit oversightQuality Management(Management review, Quality policy)Source file
2. Unplanned maintenance works due to unexpected malfunction or failure of facilities and equipment are carried out according to the ● procedure. But even the facility and equipment do not maintain expected functions, the procedure did not require impact analysis of unexpected malfunction or failure, and reporting the results of such analysis to the quality assurance unit for their confirmation. Under such situation, the unplanned maintenance work carried out in ● year and that resulted in ●, and unplanned maintenance work of WFI manufacturing equipment observed during inspection also did not subject to impact analysis. (Violation of Article 15 paragraph 1-1 of GMP ministerial ordinance.) The procedures related to unplanned maintenance due to unexpected malfunction or failure of facilities and equipment should be in compliance with the Article 15 of GMP ministerial ordinance. In addition, confrimation should be done whether there is other event of deviation defined in Article 15 of GMP ministerial ordinance for which impact analysis did not carried out or result of impact analysis was not reported to quality assurance unit. All the procedures related to Article 15 of GMP ministerial ordinance should be in compliance with the provisions of this article.
PMDAFY2024 · No.6Deviation, CAPA, and investigationDeviation controlSource file
3. The procedure of this site defines that the changes having an impact to the product quality or to the marketing authorization should be informed to the marketing authorization holder(s) of the product involved in the change, prior to the implementation, and obtain confirmation by the marketing authosization holder(s). But the procedure did not define a requirement of informing completion of the change having an impact to the product quality or marketing authorization to the imvolved marketing authorization holder(s), and actually the site did not inform such information. (Violation of Article 14 paragraph 2-2 of GMP ministerial ordinance.) The procedure should be up-dated to define requiremtnt of informing the involved marketing authorization holder(s) completion of change control procedure having an impact to the product quality or marketing authorization.
PMDAFY2024 · No.7Regulatory reporting and change controlChange controlSource file
Regarding control of document and record, the inspected site did not control listing of documents into the document list and taking out document from the document storage area based on the procedure, and locations and existence of multiple documents were unknown. There is no assurance that the GMP documents are retained for required retention period, and there is a possibility of losing necessary documents for quality assurance and important technical information. Actually there was an event of missing test record in the past. (Violation of Artucle 20 paragraph 1-3 of GMP ministerial ordinance) In addition, the conditions pointed out in the other deficiencies 2 (1), 4 (1) and 8 (1) indicate that the issues of knowlege management and training system became apparent, and the possibilities of insufficient human resources for hand over the tasks or insufficient number of personnel. Taking the above situation into consideration, root cause analysis should be carried out under the involvement of executive managements, and fundamental and adequate corrective and preventive action should be taken. Regarding the corrective actions against the deficiencies of document and record control, at least following actions should be included: ・ Confirm loss or existence of missing GMP documents or records, and all other critical GMP documents for which location confirmation are not done, and report the results. ・If loss of any of the GMP documents are confirmed, deviation procedure should be applied and necessary actions should be taken, including analysis of impact to quality assurance and regulatory procedures.
PMDAFY2024 · No.8Documentation and recordsControl of document and record (including data integrity)Source file
1. A deficiency was observed regarding the retention period of the documents and records of the inspected product (hereinafter referred to as documents). The procedure defined that the manufactuirng instruction and record should be retained for ● years of the shelf life of the product plus 10 years, total ● years. But retantion preiods of other documents than manufacturing instruction and record are defined as ● years of shelf life or one year. Because the inspected product is categorized to biologica drug product, longer document retention period is required to make possible to investigate the cause relationship in the event of occurence of adverse drug event in the patient administered with the biological drug product, the procedure of the inspected site did not comply with this requirement. (Violation of Article 30 paragraph 2 of GMP ministerial ordinance) The procedure should be up-dated, to retain GMP documents for adequate periods based on Article 30 paragraph 2 of GMP ministreal ordinance. In addition, confirmation should be done whether there are any documents or records related to the manufacturing control and quality control of drug products intended for the Japanese market and the documents and records of process validation related activities, which are already discarded prior to the period required by the GMP ministerial ordinance. And if such discarded document or record is confirmed, evaluation of impact to the product quality or to the product validation by discarding shoud be done.
PMDAFY2024 · No.9Documentation and recordsControl of document and record (including data integrity)Source file
2. Storage and reconciliation of the starting material are controlled and recorded using a manufacturing control system. But the reconciliation of raw material ● described as the active ingredient in the marketing authorization dossier and the materials used in the manufacture are not recorded. (Violation of Article 10 paragraph 6 of GMP ministerial ordinance) To be able to trace that adequate raw materials and packaging materials are used for manufacture, establish a control procedure of them, and record of reconciliation of those materials.
PMDAFY2024 · No.10Documentation and recordsManufacturing instruction・ record, proceduresSource file
3. Reconciliation and related records of working standards used for product release test, including use date, used amount are not recorded. (Violation of Article 11 paragraph 1-2 of GMP ministerial ordinance) Control procedure for analytical standards should be established to make possible to trace back that adequate standards are used for laboratory tests, and record the reconciliation according to such procedure.
PMDAFY2024 · No.11Laboratory and QC controlsTest instruction ・ record, laboratory proceduresSource file
1. As the result of self audit by the inspected manufacturing site revealed records of discrepant opreations from instruction or records that do not reflect actural operation. As a corrective action, this site carried out training of the personnel regarding data integrity total ● times from ●month ●year up to the date of our inspection. But during current on-site inspection, multiple events of compromysing data reliability were observed as follows: (Violation of Article 20 paragraph 2 of GMP ministerial ordinance) (1) Recording. 1) The procedure for processing of spraying ● to ● and mixing, for the manufacture of ● capsule ● (Batch No. ●) defines that the operation should be recorded each time processing of one bag is completed. But during inspection, even the operation is ongoing and there was an operation that should be recorded as per the procedure, that operation was not recorded. 2) ● events of empty record of pre-use cleaning and error check at the start, in the use log of ●, even the test using ● is on-going. In addition, there were ● events of recording post use cleaning even the test is on-going. 3) There were ● events of missing record of routine check that should be done before starting the test in the use log of ●, even after the test was completed. 4) Samples of multiple lots of multiple products for the tests of ●, ● and ● are heated in crucibles. The procedure of this test defined to record the name of product tested, lot number, test item, identification number of the crucible in the log book of crusible for traceability. But the log book was not recorded even the test is ongoing. (2) Issuance of blank record form. 1) In addition to manufacturing instruction and record, manufacturing unit uses multiple records that are not linked to the procedure such as ●. Blank forms of those records are not controlled for issuance, and the staffs in the manufacuturing unit can freely print out. (3) Control of records. 1) The results of in-process control of …
PMDAFY2024 · No.12Documentation and recordsControl of document and record (including data integrity)Source file
2. There was an OOS test result in the dissolution test of ● tablet (batch No. :● ) during the stability monitoring at ● year time point. No laboratory error was identified in the laboratory investigation, and the confirmatory test again resulted in OOS. Based on those results, the inspected site assumed a possibility that the OOS event was the result of picking up the test sample with a delayed disintegration of coating film. After that they carried out 5 times repeated tests and because all the results complied with the specification, they concluded that the product comply with the specification. Relevant procedure in this site defines, even the confirmatory test again gave OOS result, If all the results of retests carried out after that meet the specification, the original result can be invalidated. Scientific rationale for such procedure was not provided. A possibility was not denied that the product lots including the lot of ● tablet, which should not have been judged to comply with the specification were approved. Based on the above points, reevaluation of the lot of ● tablet should be done including the result of reconfirmation test of OOS result, and check the existence of similar events and report the result and actions to be taken. In addition, the OOS procedure should be revised to be able to evaluate OOS result adequately with scientific rationale. (Violation of Article 11 paragraph 1-8, and Article 11-2 paragraph 1-4 of GMP ministerial ordinance)
PMDAFY2024 · No.13Laboratory and QC controlsDeviation control in laboratory, OOS/OOT controlSource file
1. The inspected site explained that room ● of ● used for the warehouse of ● do not store documents and records for which control under GMP system (hireinafter referred to as records) is required. But actually multiple GMP records are stored and the location and existence of GMP records were not completely understood. It is unclear whether the retention control of those records are assured for required retention period, and there was a possibility of loosing necessary quality assurance data or critical technical information. Actually there were following events of missing records or records with high probability of missing, even those are within the required retention period. (Violation of Artucle 20 paragraph 1-3 of GMP ministerial ordinance) Check the control status of GMP records used throughout all the GMP related operations in this site, whether there is other document which is not retained for required period. After that, root cause of the deficiency should be investigated and implement corrective actions. (1) Record of trainig carried out ● month ● day ●year is missing at the time of inspection. Regarding the periodical training for all the personnel in this site, training records in the manufacturing unit were retained, but the training records in the quality unit were not retained. (2) Monitoring by sedimentation test was carried out in ● as an investigation for a complaint. There was a description indicating the existence of an attachment describing the monitoring locations for the sedimentation test, in the note column of ● for this monitoring, but the attachment was missing at the time of inspection..
PMDAFY2024 · No.14Documentation and recordsControl of document and record (including data integrity)Source file
2. Following deficiencies were observed regarding failure to the reliability of records. Additional deficiencies in records were observed as described in other deficiencies 1 and 8. In addition, the inspected site did not assign the responsible person ensuring reliability of records, as defined in Article 20 paragraph 2 of GMP ministerial ordinance. (Violation of Article 20 paragraph 2 of GMP ministerial ordinance) (1) An incomplete batch manufacturing instruction and record of ● tablet ● (Lot No.: ●) was retained in a personal letter case of ●. On the other hand, official batch record of this lot was separately kept. As the result of comparison of those two records, discrepancies in the time of start of operation, weight of intermediate product after ● process, and yield of this process. (2) Manufacturing records of multiple lots of ● granule recorded the weighed amount of active ingredient ● as ● kg for all the lots. The site personnel explained that they compare the amount indicated in the instruction and the reading of the weighing balance, and confirm there is no significant difference, then record as ● kg for all of them. This practice indicate that they don't record accurate reading of weighing balance and there is a possibility that the weighed amount of active ingredient do not reflect the amount of marketing authorization. (3) Cleaning of ● room after completion of manufacturing of ● tablet ● (Lot No.: ●) was on-going, but the hygine control record was already recorded that the cleaning was completed and the signature of confirmation was done. (4) The dissolution test of the sample of ●th year in the stability monitoring of ● granule ● (Lot No.: ●) was not completed at the time of inspection, but the report of product quality review (hereinafter referred to as APQR) descrubed results of all the test including dissolution test and concluded that all the test results were within the specifications. Taking those situations into consideration, and in …
PMDAFY2024 · No.15Documentation and recordsControl of document and record (including data integrity)Source file
3. Differencial pressure between the rooms inside the work area classified as class 100,000 is controlled by setting the highest positive pressure for the non-dedicated corridor and the work rooms were controlled to be negative pressure against the non-dedicatied corridor. The non-dedicated corridor should be controlled to clean condition to prevent contamination of each work room under such setting of the pressure difference, but the corridor was extensively contaminated with powder and looked white. Cleaning procedure for the corridor was not established and there was no cleaning record. In addition, sufficient actions to prevent cross-contamination among different products were not taken including the absence of dust removal measures at the time of moving to other work room. In addition, as indicated in other deficiency 5, other deficiencies in the control status of manufacturing equipment were observed. (Violation of Article 8-2 of GMP ministerial ordinance) Following actions should be taken, taking above situation into consideration: a. Confirm that dissemination of the powder observed in non-dedicated corridor to each work room did not occur. Evaluate the risk of occurence of cross-contamination of products and report the results b. Establish cleaning procedure of non-dedicated corridor, and other places identified to be lack of cleaning procedure by the above check. In addition, carry out an audit that the cleaning is adequately done according to the established procedure. c. Check existence of similar situation in other area, investigate the root cause of insufficient cross-contamination prevention measures, and implement adequate CAPA.
PMDAFY2024 · No.16Contamination controlContamination controlSource file
4. During the inspection of the manufacturing equipment for ● granule in room ●, residues of powder were observed on the surface of inside and out side of the equipment, even the status of the equipment was labeled as cleaned. Though the equipment is dedicated use, adequacy of cleaning procedure was not verified. Because the active ingredient of this product has ● characteristics, a possibility of impact to the product quality by the carry over is not denyed. (Violation of Article 9 paragrapah 1-1 of GMP ministerial ordinance) Based on the above points, following action should be taken: a. Evaluate adequacy of the cleaning procedure of the equipment taking the characteristics of the product into consideration, and evaluate the impact of carry over of the residue to the quality of this product. b. Check existence of similar event in other equipment, investigate root cause of absence of adequate evaluation for the necessity of cleaning validation, and take adequate CAPA.
PMDAFY2024 · No.17Cleaning validationCleaning and Cleaning ValidationSource file
5. The procedure for handling OOS events does not necessarily require root cause analysis nor implementation of CAPA, even no laboratory error or sampling error was identified in the initial phase investigation. Actually some events of absence of root cause investigation were observed as descrubed in the major deficiencies 6 and 7(4). (Violation of Article 11 paragraph 1-8 of GMP ministerial ordinance) The OOS procedure should define that root cause should be investigated and necessary corrective action and preventive action should be taken in the event of obtainig out of specification result. In addition, check the existence of any OOS event for which root cause investigation is not carried out, and take necessary action according to the up dated procedure.
PMDAFY2024 · No.18Laboratory and QC controlsControl of laboratory error, OOS/OOTSource file
6. In response to the observed deficiency during the GMP inspection in ● month ● year, the inspected site revised the procedure to carry out release test on the finished product not the intermediate product, if the identity of quality between intermediate product and finished product is not confirmed. Because the product of ● granule (Lot No.: ●) complied with the release test on the intermediate product before the above revision of the procedure, the inspected site carried out the release test again on the finished product, and obtained failure result in the dissolution test. After that this site did not distribute the lot, but they did not carry out impact analysis to extend other lots already distributed based on the satisfactory result of release test of intermediate product. In addition, root cause analysis of non-compliance to the specification was not carried out, nor any CAPA was implemented. (Violation of Article 11 paragraph 1-8 of GMP ministerial ordinance) Taking the above situation into consideration, following action should be taken: a. Carry out release test for the lots distributed based on the complied results of release test on intermediate product, at least for the lots within the expiration date, and report the results. If the result do not comply with the specification of the drug product or there is a possibility of non compliance, inform that to the marketing authorization holder (herein after refferred to as MAH) immediately. b. Investigate the root cause of the failure to meet the product specification of the above lot, according to the procedure revised in response to the major deficiency 5, and implement adequate CAPA.
PMDAFY2024 · No.19Laboratory and QC controlsControl of laboratory error, OOS/OOTSource file
7. Multiple deficiencies were observed in relation to the stability monitoring as follows: (1) The inspected site explained that the samples in the stability monitoring program are taken from the stability chamber at the time point of 1 year, 2 years and ● years after the start of storage, and analytical tests of the samples are carried out within one month of taking out from the chamber. But the analytical tests of total ● samples were delayed at the time of current inspection. Among them, ● samples should have been tested one and a half year ago, ● samples should have been tested one year ago, and ● samples should have been tested a half year ago. (Violation of Article 11-2 paragraph1-3 of GMP ministerial ordinance) (2) During the review of APQR record for year ● reviewed for all the finished products, it was noted that some lots of multiple products revealed adverse trends in some test items, but no action was taken, including evaluation of possibility of exceeding the specification within the expiration period, inclease the testing frequency, or root cause analysis. In addition, those products include the above described delayed stability monitoring test lots, and a possibility that the products not complying with their specifications may be distributed in the market. (Violation of Article 11-2 paragraph 1-4 of GMPministerial ordinance) 1) The specification of dissolution test of ● granule ● is defined to be not less than ●%. APQR reported that one lot of this product (Lot No.: ●) revealed a decrease of the value to ●% at one year and ●% at two years. 2) The specification of dissolution test of ● tablet ● is defined to be not less than ●%. APQR reported that one lot of this product (Lot No.: ●) revealed a rapid decrease of the value from ●% of the release test to ●% at one year and ●% at two years. 3) The specification of dissolution test of ● tablet ● is defined to be not less than ●%. one lot of this product (Lot No.: ●) revealed a decrease of the value from …
PMDAFY2024 · No.20Stability and storageStability monitoringSource file
1. Following events were observed related to reliability of records, including the cases of recording different information from the facts, or cases of absence of required record (Violation of Article 20 paragraph 2 of GMP ministerial ordinance) In addition, other deficiencies related to the reliability of reords were observed, as indicated by other deficiencies 1(2), 1 (3), 3, 9, 11, 12 and 15 (1). (1) In the cleaning record of each work room within clean area on the date of inspection, ● day ● month ● year, the check boxesof ● which indicate those rooms were cleaned were checked. The cleaning record indicated a cleaning method which uses drinking water, purified water and 75% ethanol as sanitizer. But preparation record of the ethanol sanitizer could not found. The operator explained that they did not use ethanol during cleaning, and a record different from the actual operation was recorded. (2) There was a record in ● (● day ● month ● year) that 75% ethanol was prepared by diluting 95% ethanol with water. The procedure for preparation of this sanitizing solution defined to use 95% ethanol. But this site did not purchase 95% ethanol since ● year, instead, purchased absolute ethanol. According to the explanation by this site, they recorded that 95% ethanol was used according to the instruction by the procedure instead of actually used absolute ethanol. The record shown to the inspector described different record from the actual operation, (3) The procedure defined that the equipment used in the clean area should be sanitized before and after using for manufacturing operation. But from ● month ● year up to the the time of current inspection, the available preparation records for sanitizing agent for equipment were only those descrubed in the above (2), and this suggest that the preparation records of sanitizer for equipment did not adequately recorded for about a half year. In addition, the status label for ● vessel used for ● described date and time of cleaning …
PMDAFY2024 · No.21Documentation and recordsControl of document and record (including data integrity)Source file
2. Following events were observed that do not comply with Article 19-2 and -4 of GMPministerial ordinance relating to the procedure and actual practices for training. And the situation of this site suggested a possibility of defects in the efficacy of whole aspect of training, as indicated in other deficiency 2 and 3 of observation of additional deficiencies for training, inadequate situation of reliability of records identified in major deficiency 1, the situation of inability of carrying out necessary operations as indicated in other deficiency 17. Corrective actions should be taken that effective trainings are continuously carried out. (1) Annual training schedule was prepared for the training necessary for the personnel engaging in manufacturing and quality related operations and used for control of training. But the procedure did not define the procedure to report the progress of training that the trainings are carried out as planned, to QA and responsible person in the Quality unit (hereinafter referred to as QP), and the plant personnel explained that QA unit and QP do not know the current status of planned training. In addition, there was no procedure that the responsible person of each unit confirm the training record of their unit. (2) The procedure did not define that the efficacy of training should be evaluated periodically and the procedure should be improved if necessary. Actually, the frequency and the contents of training were not evaluated until now.
PMDAFY2024 · No.22Training and personnelTrainingSource file
1. Multiple instances of changed work procedure or testing procedure without carrying out change control procedure were observed. (Violation of Article 14 paragraph 1 of GMP ministerial ordinance). There was a possibility of failure to conduct adequate risk evaluation of those changes on the product quality by skipping change control procedures, in addition, there were other risks of difficulty in checking existence of changes relating to the batch under reviewing for batch release procedure, or risks of making difficult to investigate root cause of the quality defect events. The events for which change control procedure were not carried out are as follows: ・Event 1: Change in in-process pH measurement method ・Event 2: Change in cleaning method of equipment after use ・Event 3: Initiation of integrity test of ● filter ・Event 4: Revision of master manufacturing instruction and record ・Event 5: Extend the expiration period of the product from ● year to ● year Following action should be taken as the corrective actions: (1) Thorough investigation should be done to check existence of other events in which changes were made wihtout carrying out change control. (2) Root cause of skipping the change control procedure for the events including the events identified in the above (1), and take preventive actions in accordance with the idenficied root cause for each event. (3) Carry out retrospective re-evaluation of the events for which change control were skipped, to check whether the actions taken at the time of change were sufficient, according to the procedure of change control.
PMDAFY2024 · No.23Regulatory reporting and change controlChange controlSource file
2. Multiple events of non-compliance to the procedure defined by the inspected site relating to the actual conduct of manufacturing control, as identified in major deficiency 1 and other deficiencies 6-(2), 6-(4)-2), 7-(1), 9-(2), 12 and 15. (Violation of Article 10-2 and -3 of GMP ministerial ordinance) Investigation of root cause of the events of non-compliance to the written procedures should be done, including investigation to the understandings of the operator to the written procedures, root cause of unawareness to those events under the current contents and frequency of training and by the current self audit, and take corrective actions according to the identified root cause.
PMDAFY2024 · No.24Quality unit oversightQuality Management(Management review, Quality policy)Source file
The actural situation of the manufacture of a sterile product manufactured by aseptic processing in this site was described below, and rational evidence were not shown that adequate and sufficenet evaluations and controls are carried out regarding absence of impact to the sterility of the product and expected cleanliness is continuously kept under such situation. (Violation of Article 24-1 of GMP ministerial ordicance) Evaluate the impact of the event of abnormally increased airborne particulates in grade A area during filling process of a lot and report the evaluation rerults. In addition, from the viewpoint of preventing release of contaminated or possibly contaminated products, check the conditions of time dependent deterioration of premices and equipment system or understand the contamination risk associated with outbreak of an event in this system, and reconsider the control method so as to assure to keep the cleanliness of the work environment continuously to the expected level, referring to the guidelines such as PIC/S GMP guideline. ・Levels of airborne particulates of ³5.0 ㎛ were not controlled inside the ● of the Grade A area in the inspected site. The monitoring records between ● day ● month ● year and ● day ● month ● year recorded multiple instances of counting particulates of ³5.0 ㎛, but since the site did not control the particles of this size by setting the acceptable limit, no action has been taken and there was a concern that the clean envilonment necessary for the manufacture of sterile drug products is maintained. ・Sedimentation test and surface microbes were not monitored in all the Grade B and C area of the inspected site including immediate supporting area for finished sterile product filling area. Because cleanliness of Grade B environment necessary for protecting Grade A could not be evaluated under this situation, this control status is not appropriate and pause a risk of unidentified contamination risk of Grade A environment.
PMDAFY2024 · No.25Contamination controlHygine control (Insect control, contamination control, environmental control)Source file
The inspected site did not have a procedure for informing marketing authorization holder when a change having impact to the product quality is implemented. (Violation of Article 14 paragraph 2-2 of GMP ministerial ordinance) Necessary procedure should be established so that the inspected site inform above change to the involved marketing authorization holder without fail.
PMDAFY2024 · No.26Regulatory reporting and change controlChange controlSource file
The inspected site processed one lot (Lot No.: ●) of returned API due to a complaint of foreign material. To remove the foreign material, the site carried out from the purification process to the final API of routine manufacturing, using returned API instead of crude API. Though the inspected site called this processing as "reprocess", the batch scale were decreased to about ●% and ●% of the routine batch scale and not the reproduction of the validated process. Carrying out reduced scale manufacturing without optimizing the equipment parameters or process parameters may considered to cause change in solvent replacement rate in cristal washing at filtration process or change in heat load at drying process, but this site skipped change control procedure and did not stury technical aspect of such changes in the manufacturing scale including process validation to verify impact to the product quality. In addition, the batch scale of this processing did not conform to that of master file (hereinafter referred to as MF). (Violation of Article 14 of GMP ministerial ordinance) When a drug manufacturer intend to change the batch scale of a product, evaluation of the impact to the product quality and marketing authorization should be done under the change control procedure and carry out necessary studies including re-validations, then implement the change. In addition, ask for judgement of the marketing authorization holder regarding the disposition of the already distributed relevant product.
PMDAFY2024 · No.27Regulatory reporting and change controlChange controlSource file
In the inspected site, total ●●● of deviations occurred from ● month ● year to ● day ● month. Almost all of them left open after passing through the dead line of reporting root cause investigation results defined in their procedure. Since the procedure defined that the impact of deviation should be evaluated after root cause investigation, it is not considered that the impact of the deviation are evaluated timely and adequately, and there is a risk of not taken prompt actions for critical deviations including informing the marketing authorization holder. Investigate the root cause of left over of many deviation events, and take preventive action. Check all the events for which root cause investigation are delayed, wheter there are events for which impact to product quality is concerned, and report the results. (Article 15 paragraph 1 of GMP ministerial ordinence)
PMDAFY2024 · No.28Deviation, CAPA, and investigationDeviation controlSource file
1. The inspected site planned to contract acceptance test of more than ● incomming raw materials to third party contract testing organizations. At the time of inspection, confirmation of acceptability of the contract testing organizations was not completed, and contract agreement with some of the testing organizations were not concluded. (Violation of Artucle 11-5 paragraph 1 and 2 of GMP ministerial ordinance) Under such situation, most of the results of acceptance test were not available yet, and APIs used for the manufacture of the marketed finished drug product, and ● finished drug product were manufactured using the incoming raw materials accepted only by checking the supplier's certificate of analysis. (Violation of Article 11 paragraph 1-4 of GMP ministerial ordinance) Qualification of contract testing organizations should be promptly completed, and after that contract agreement should be concluded, then complete the acceptance test of all the raw materials. Take deviation procedures for the use of raw materials in the manufacture of API and ● finished drug products which are not yet tested, then make it clear the scheduled date of obtaining the test results, and steps to be taken after obtaining the test results, then impact analysis to the product quality should be done. Report the content of contract agreements after conclusion and the results of raw material tests after completion of the tests. Standards and procedures related to raw material control should be established to clearly define that when the raw materials are tested by contract testing organizations, contract agreement should be concluded with the qualified testing organization, then acceptance test should be done under the agreement and only approved materials should be used for manufacture. Carry out trainings related to such standard and procedures to all the involved personnel.
PMDAFY2024 · No.29Material and supplier controlControl of supplier and third party contractorSource file
2. Following deficiencies were observed regarding the validation of the test methods (hereinafter referred to as "method validation") of raw materials, packaging material, active ingredient, and ● drug product. (Violation of Article 13, paragraph 1 and 2 of GMP ministerial ordinance) Adequate corrective actions to the following deficiencies should be taken by setting practical dead line to completion. To comply with the timely conduct of the analytical validation works, relevant procedures should be established and train the involved personnel. (1) The validation master plan for the inspected product did not define necessity of method validation nor the test methods for which method validation is required, and protocols for method validation were not prepared. In addition, there were no validation reports at the time of inspection. Master plan for validation of test methods related to the inspected product should be established and protocols for validation of each test method should be prepared based on the master plan. If any of the test methods are obtained by technology transfer, obtain the method validation report from the originator, and check the extent of necessary validation/verification so that the same level of test results are obtaind with the originator. Verification of compendial test methods should be done to confirm that the samples tested in this site can be analysed adeqately as directed in the compendium. Submit following documents summarizing the items to be implemented for corrective actions; a list of all the tests related to the inspected product (including inhouse in-process test methods), necessity of method validation for each of the listed tests, items to be evaluated in the method validation tests, and testing schedule. Carry out the validation according to the schedule and submit the reports. (2) The inspected site planned to carry out velification tests to confirm adequacy of transferred specifications and test methods for API and ● …
PMDAFY2024 · No.30Validation and qualificationValidation (method validation)Source file
3. Among the responsible managers defined in GMP ministerial ordinance, the manager controlling the third party contractors and the manager responsible for ensuring the reliability of records are not appointed, and the related procedures did not define the duties of such personnel. (Violation of Article 11-5 paragraph 1, and Article 20 paragraph 2 of GMP ministerial ordinance) And as observed in major deficiency 1 related to the control of third party contractor, and in other deficiency 5 related to the reliability of records, there were duties for wich adequate controlls were not implemented. Managers who have enough knowlege of the duties should be appointed, establish written responsibilities and authorities for the appointed duties, establish the system to carry out the duties, and carry out training
PMDAFY2024 · No.31Quality unit oversightGMP organization (Organizational structure, responsibilities of senior management)Source file
The terminal sterilization process of ● cyringe ● manufactured in ● is carried out under the conditions to assure ●, and employed combination of BIs and bioburden for setting sterilization conditions. As the result of reviewing the sterilization validation of the inspected product, part of the data necessary for demonstrating adequacy of biological parameters for sterilization validation were missing as indicated in the following (1) and (2). (Violation of Article 13 paragraph 1 of GMP ministerial ordinance) Investigate the root cause of insufficiency in the sterilization validation of the inspected product, and evaluate the impact of such insufficiency to the sterility of previously manufactured products, and take necessary corrective actions including additional validation. (1) The characteristics of BIs used for challenge test during the initial sterilization validation carried out in ● year were unknown due to the following reason; 1) ● was selected as the microbial species for BIs, but the adequacy of this species was not shown. 2) The inspected site prepared spore suspension by incubating a microbial species, and prepared BIs using the drug product as a carrier. But the site did not have information for D-value and its scientific basis of the prepared BIs, and the D-value of the BIs was not measured. 3) There was no preparation record for BIs. (2) A heat penetration test under loaded pattern, was done during periodical revalidation, but there was no BI challenge test, and the rationale that this test is not necessary was unclear.
PMDAFY2024 · No.32Validation and qualificationQualification of premices and equipment (DQ, IQ, OQ, PQ, CSV, calibration)Source file
Following deficiencies were observed related to cleaning practices and cleaning validations. Cleaning validation should be adequately carried out to prevent cross contamination between other products sharing the equipment with the inspected product ●, and routine cleaning operation should be adequately controlled and recorded. In consideration to the observed deficiencies of inadequacies in cleaning validation, cleaning procedures and creaning records, carry out impact evaluation to the already distributed ●, root cause investigation of those deficiencies, and report the results of such evaluation and investigation. (1) First version of cleaning procedure was established on ● day ● month ● year, and it was revised on ● day ● month ● year. Cleaning practices before establishing the first version of cleaning procedure could not be confirmed. The first version did not define the parameters for cleaning, including amount of cleaning solvent used, duration of cleaning, etc. (2) The cleaning validation study carried out for the cleaning of ● in ● year was insufficient due to the following reason; 1) Number of cleaning run for verification was only one, but there was no reasonable supporting evidence. 2) Non-dedicated equipment including precipitation tank, receiving tank for receiving a treated solution, and the piping for those tanks were not subjected to the cleaning evaluation. 3) Recovery rate of swabbing was evaluated for stainless steel material, but the recovery rate for other materials contacting with ● and its intermediate products were not checked. 4) Detection limit and quantitation limit of the analytical methods for cleaning efficacy were not determined. The analytical methods could not assure adequately that the residue is less than the set acceptable linit. 5) The samples for cleaning efficacy inside the reactors were taken by swabb method. As the swabbing location, connecting part of the reactor was selected. This location is upper than the surface of the …
PMDAFY2024 · No.33Cleaning validationCleaning and Cleaning ValidationSource file
Regarding the evaluation of cleaning efficacy of the equipment used for the manufacture of the inspected product, cleaning validation protocol was established in ● year. The protocol defined to carry out cleaning validation after manufacture of not less than 3 lot of the product. Then, manufacture of products were actually done for not less than 3 lots as defined in the protocol, but as of ● day ● month ● year, cleaning validation record was not reported. The inspected site carried out cleaning verification studies by cleaning the equipment with the previously defined procedure at the time of product change over, and confirmed that the residual amount is lower than the set acceptance limit. But they did not explain adequate reason why they did not carry out the cleaning validation study in accordance with the protocol established in ● year. The inspected site explained that one reason for not carrying out the cleaning validation is change in company affiliation and personnel changes that resulted in inadequate control. (Violation of Article 13 paragraph 1-2 of GMP ministerial ordinance) Taking the above situration into consideration, following actions should be taken; (1) Promptly carry out evaluation of adequacy of current cleaning procedure for the related products and establish the cleaning procedure. Please note that there is a possibility of insufficient cleaning efficacy under the current cleaning procedure, and actions should be taken considering such possibility. (2) If the inspected site specify that only verification is required for evaluation of cleaning efficacy for the manufacture of pharmaceutical products, reconsider that the related procedures to assure the cleaning methods should be basically in accordance with the validated methods. (3) Check existence of other quality events related to validation or deviations similarly left over during the change in company affiliation, and control the progress of such issues adequately.
PMDAFY2024 · No.34Cleaning validationCleaning and Cleaning ValidationSource file
1. Following deficiencies were observed related to the cleaning of ● tank and cleaning of the filter for filtration of ●. Take adequate corrective actions for those events. (Violation of Article 9 paragraph 1-1 of GMP ministerial ordinance) (1) Though the ● tank was under cleaned status, white foreign matter was observed inside of the tank. The inspected site explained that the foreign matter is estimated as microorgainsm. Identification should be done for the white foreign matter, investigate the root cause of the foreign matter, and take corrective action. In addition, evaluate the impact of the white foreign matter and take necessary actions based on the evaluation. (2) The filter used for filtration of ● was observed partly brown colored, even it was under cleaned status. Investigate the root cause of the color, evaluate the impact to the product quality, and take necessary corrective actions. (3) The site personnel explained for the cleaning method of ● tank, that they wash the upper part of the tank by flushing sodium hydroxide solution, but this method was not defined in the procedure. The site personnel further explained that the operators know this by on the job training, but the training record of this procedure was not prepared. As the result, it was not ensured that the ● tank was adequately cleaned using the validated method. Define the cleaning method of ● tank adequately in the cleaning procedure, carry out the training of such cleaning procedure and record such training. Check the necessity of revising the cleaning procedure of ● tank, taking the situation of the above (1) into consideration.
PMDAFY2024 · No.35Cleaning validationCleaning and Cleaning ValidationSource file
2. Quantitative analysis of ● of ●, and quantitative analysis of ● were carried out by the methods described in the marketing authorization of this product, as described below; (Violation of Article 3-2 of GMP ministerial ordinance) (a) The inner diameter of the column used for the HPLC method was ● mm, different from the defined size of ● mm in the test method of marketing authorization. (b) The marketing authorization defined that the flow rate of the movile phase of the HPLC method should be adjusted so that the retention time of the eluate to be the set time (minutes). But the inspected site did not adjust the flow rate and the retention time of the eluate did not correspond to that of marketing authorization. (c) The marketing authorization defined that system suitability test should be done using internal standard, but the system suitability test using internal standard was not done. Following corrective actions should be taken against the above deficiencies; (1) Check the test mentods of the product ● and ● including in-process tests and intermediate product tests, whether there are additional discrepancies with the test methods in the marketing authorization. (2) Identify the scope of the tests carried out using different test methods from those in the marketing authorization. Then evaluate the impact to the product quality, and take necessary actions. (3) Investigate the root cause of the discrepancies in the test methods between the marketing authorization and the actual method. Investigate the root cause of the failure to identifying the discrepancies with the marketing authorization in this site including QA unit, and take corrective actions.
PMDAFY2024 · No.36Regulatory reporting and change controlRegulatory complianceSource file
We checked a copy of a manufacturing record for ● (Lot: ●) submitted on ● day ● month ● year prior to the inspection, and calcucrated the actual loading amount of water in the ● process from the recorded amount of the flow meter and obtained the result of ● kg which exceeded ● kg to the instructed ● kg. On the other hand, when we checked the original record in the manufacturing site during inspection, the record of flow meter was revised to align with the instructed amount of ● kg on ● day ● month ● year. As the result of checking adequacy of this record, multiple deficiencies having an impact to the reliability of records were observed as follows; (Violation of Article 20 paragraph 2 of GMP ministerial ordinance) (1) When we requested an explanation for the discrepancy between the copy of a manufacturing rocord submitted as pre inspection documents and the original record, the inspected site acknowleged the back dated revision of the record. (2) A QA personnel in charge of document storage found the discrepancy between the instructed loading amount of ● and the actually loaded amount early in ● month ● year and reported to the manufacturing manager. The manufacturing manager interviewed the operator involved in the process at the time of the event, and speculated that the excess loading may result in decreased product yield. The manufacturing manager judged that the actually loaded amount was correct and instructed to revise the record. But there was no record of the interview and the instruction to revise the record by the manufacturing manager. Investigation of the root cause of incorrect record and CAPA for such event were not done. They explained that the record of flow meter was revised by reverse calculation to make the loaded amount of ● as ● kg, but the objective evidence to prove absence of the over loading of ● kg, and correct loading of ● kg was not shown. (3) The personnel in charge of document storage in QA unit acknowleged that when the revised …
PMDAFY2024 · No.37Documentation and recordsManufacturing instruction・ record, procedures (including data integrity)Source file
1. The inspected site did not establish a document corresponding to the manufacturing instruction required in GMP ministerial ordinance. In addition, the manufacturing record did not describe instructions in the manufacturing process, and special notes and precautions to be followed. (Violation of Article 10-1 of GMP ministerial ordinance) For example, following instructions were not described in the master batch record. Batch manufacturing instruction or master batch manufacturing instruction and record describing necessary instructions and other necessary items should be established and carry out manufacturing operations according to such document. (1) Carry out re-● in the ● process. (2) Calculation method of ● to be added in the ● process, ● to be added in the ● filtration process, ● to be added in the ● process. (3) Stirring method to make the mixture uniform after addition of ● in the ● filtration process. (4) Filtration pressure in the ● filtration process. (5) Duration of concentration by filtration of ●. (6) Conditions of stirring and stand still after addition of ● in the ● process. (7) Loading pattern of ● containing trays in the lyophylizer.
PMDAFY2024 · No.38Documentation and recordsManufacturing instruction. RecordSource file
2. Sampling records of samples for product release test were not prepared. (Violation of Article 11 paragraph 1-1 of GMP ministerial ordinance). Sampling operation should be recorded for each sample in a predetermined form including place of sampling, sampling method, person who took the sample, time and date of sampling, etc., and the record shoul be kept. Same type of sampling procedure should be applied to the samples other than the finished product, including rawmaterial samples.
PMDAFY2024 · No.39Laboratory and QC controlsSampling and sample controlSource file
The inspected site did not establish a contamination control strategy (CCS), and an important tool of evaluating the effective ness of CCS, APS in this site was observed to have at leasr following 5 deficiencies. The situation of APS in this site could not make a judgement that the operation for sterility assurance is adequate. Estabilsh a CCS, check the existence of insufficient or underestimated processes related to contamination control, and carry out APS studies incorporationg worst case conditions. (Violation of Article 13, and 24 of GMP ministerial ordinance) (1) About ●●●● L of saline was used as the placebo to simulate ● used from dissolution process to ● in ● process. Only total 300 mL of the saline was incubated and remaining saline was discarded. (2) Susequent processes after the above (1) used lactose as a placebo. For about 3 kg of lactose filled in each stainless steel can, only 2.5 kg was indubated and the remaied portion was discarded. (3) The duration of keeping saline in ● did not consider the maximum number of lots processed during one campaign. (4) The site personell explained that the maximum lot size after the ● process is ●●●● kg, but the lactose used in APS is about ●● kg, and result in smaller contact area inside the ●. (5) They did not confirm that ● solution and WFI used for APS do not interfere recovery of microorganisms.
PMDAFY2024 · No.40Aseptic processing and sterility assuranceAseptic process simulation test (APS)Source file
During the stability monitoring of API ● (Lot No.: ●), test result of the time point of ● months was below the specification of ●. As the investigation (No. ●) of the out of specification test result (hereinafter referred to as OOS), retest was carried out using the retain sample of the same lot. The result was again below the specification, and further retest was carried out taking a sample from the stocked product. Because the stocked product complyed with the specification, the inspected site speculated that there is some problem in the storage condition of the stability monitoring sample and retain sample, but they didn't consider a possibility of obtaining passed result by repeating retests. In addition, the procedure of this site required to implement necessary corrective and preventive actions (hereinafter referred to as CAPA), but no CAPA was prepared. In addition ● events of similar OOS occurred in other lots of stability monitoring sample. There were description to continue to propare CAPA plan, but actually no CAPA was implemented. More than ● years have passed since this event (No. ●) occurred, root cause investigation, implementation of necessary CAPA, or the recording and retention of record were not done. Root cause of the test result of ● lower then the specification should be investigated, and take prompt CAPA. (Violation of Article 11 paragraph 1-8 of GMP ministerial ordinance)
PMDAFY2024 · No.41Laboratory and QC controlsDeviation control in laboratory, OOS/OOT controlSource file
Following deficiencies were observed in the actions teken for an OOS test result obtained during the stability monitoring of the inspected product (Lot No.: ●) at the time point of ● months in which the test result of a related substance ● was ●% (specification: not more than ●%). Adequate action shoud be taken for each of the deficiencies. (Violation of Artucle 11 paragraph 1-8 and Article 21 paragraph 2-2 of GMP ministerial ordinance) (1) Investigation of existence of laboratory error for the OOS event continued for more than one year, and various examinations were carried out during such period. Though the site personnel explained that the testing manager verbally instructed the method of laboratory examination, there was no record of such instruction and the record of such examination was not submitted. (2) ● years have passed since the occurence of the OOS until the inspeccted site informed the event to the marketing authorization holder. The relevant procedure defined that notification of OOS to the marketing authorization holder should be done after confirmation of occurence of the OOS event, and the situation of possibility of OOS or possibility of occurence of OOS are not required to notify marketing authorization holder.
PMDAFY2024 · No.42Laboratory and QC controlsDeviation control in laboratory, OOS/OOT controlSource file
Regarding the amount of retain sample, raw materials, intermediate products, and finished products should be retained twice the amount required to carry out full analytical controls on the batch, but there was a separte provision that permit to retain the amount of one time of full analytical controls in the case of ●, in violation of Article 21 of GMP ministreal ordinance. When we checked the actual storage of the retain samle of ●, only the amount of one time of full analytical control was retained. Though the provisions of the retain sample in the agreement among the inspected site, in-country care taker, and the marketing authorization holder complied with the requirement of GMP ministerial ordinence, actual practice was continuously done in accordance with the above procedure prior to the signed date of the agreement. Control of retain sample should be done according to the requirement of GMP ministerial ordinence. In addition to the above situation, the deficiencies described in other deficiencies 2 and 5 indicate that the communications between the inspected site and the marketing authorization holder do not permit adequate transfer of necessary information, and result in insufficient mutual understanding leading to a possility of non-complied manufacture of drug products with the GMP ministreal ordinance or marketing authosization. Root cause of insufficient communication between the inspected manufacturing site and the marketing authorization holder should be clarified and take adequate corrective actions.
PMDAFY2024 · No.43Laboratory and QC controlsRetain sample, retention sampleSource file
There were several cases of non-compliance with the GMP Ministerial Ordinance as shown below. Evaluate the discrepancies between the current procedures at the manufacturing site and the GMP Ministerial Ordinance and report the result. Also, improve the procedures to comply with the GMP Ministerial Ordinance. (1) The product quality review items did not include an evaluation of raw materials and other materials, and periodic evaluations had not been performed. Conduct periodic evaluations to ensure appropriate and smooth manufacturing and quality control of raw materials as specified in Article 11-4, Paragraph 1, Item 3 of the GMP Ministerial Ordinance. (2) For the raw materials designated as "those impacting product quality", the manufacturing site under inspection had not concluded necessary written agreements with suppliers on the manufacturing and quality control. Conclude and manage required written agreements with supplier for raw materials that impact product quality, as stipulated in Article 11-4, Paragraph 2 of the GMP Ministerial Ordinance. (3) No procedure was in place for notifying the marketing authorization holder and the domestic caretaker registered in the drug master file of changes that impact product quality or approved product information. As specified in Article 14, Paragraph 2, Item 2 of the GMP Ministerial Ordinance, notify the marketing authorization holder of the product and the person granted approval under Article 19-2, Paragraph 1 of the PMD Act if any changes impacting product quality or approved product information occur. Also, establish procedures for recording such notifications and implement them appropriately.
PMDAFY2023 · No.1Quality unit oversightOrganizational management, quality managementSource file
1. An event in which the manufacturer's authorized person did not perform the operations appropriately was identified as described below. Investigate the cause of the event and take necessary measures so as not to hinder the performance of the manufacturer's authorized person. For (2), promptly investigate the cause of the discrepancy and conduct re-inspection using the improved method. (1) The operating procedures "X" and "X" that correspond to the operations newly required after the revision of the GMP Ministerial Ordinance in 2021 were not established until MM YYYY. Although the quality policy of the manufacturing site states "X", the manufacturer's authorized person failed to appropriately supervise the situation where the violation of the Ministerial Ordinance remained unsolved for 2 years. (Article 5, Paragraph 1, Item 1 of the Ministerial Ordinance) (2) For X Tablets X and its drug substance X, the approval document specifies that “the particle size of X is X to X µm” must be confirmed during the acceptance testing process. However, an inspection of discrepancies requested by the marketing authorization holder and conducted in MM 20YY revealed that no procedure had been established for checking and recording the particle size, nor had any documentation serving as the basis for the check been retained. When this case was handled as a deviation, no re-inspection of other products was instructed despite the fact the deficiency had been recognized during the past inspection of discrepancies. (Article 5, Paragraph 1, Item 3 of the Ministerial Ordinance) (3) Although the Quality Assurance Unit recommended the need for sufficient investigation of the cause of the occurrence of quality information described in Other Deficiency 1 (e.g., stopping the production and disassembling the device to check), the management, including the manufacturer's authorized person, did not issue any instructions. (Article 5, Paragraph 1, Item 3 of the Ministerial Ordinance)
PMDAFY2023 · No.2Quality unit oversightOrganizational management, quality managementSource file
2. The "Procedure X" did not clearly provide any specific activities to be conducted for the continuous assurance of reliability of the written procedures and the records in accordance with the GMP Ministerial Ordinance. Also, no document had been prepared to designate a responsible person for the relevant operation. Designate a responsible person immediately and establish written procedures. Also, conduct a site-wide data integrity risk assessment and implement measures for risk reduction. (Article 8, Paragraph 2 and Article 20, Paragraph 2 of the GMP Ministerial Ordinance)
PMDAFY2023 · No.3Data integrityDI-relatedSource file
3. In addition to Major Deficiencies 1 and 2 above, written procedures and records were not properly prepared in accordance with the GMP Ministerial Ordinance. For example, no document was available designating a person responsible for the management of external contractors (Article 11-5, Paragraph 2 of the Ministerial Ordinance), and no record of the investigation of the cause of quality information was maintained (Article 16, Paragraph 1, Item 3 of the Ministerial Ordinance). Conduct a gap analysis to identify any discrepancies between the GMP Ministerial Ordinance/the Notification of Promulgation and the written procedures and records controlled by the manufacturing site and implement necessary corrective actions.
PMDAFY2023 · No.4Quality unit oversightOrganizational management, quality managementSource file
The approved reference standards specified in the approval document was not used for the quantitative assay and dissolution testing among the release testing for X Tablets. Instead, the drug substance was used as a reference standard. Furthermore, the reference standard used had not been tested in accordance with the specifications and testing methods specified in the approval document nor had it been qualified using the designated reference standard in the approval document. The Manufacturing site explained the control system for the reference standard identified in the inspection had been in place since the beginning of production. Conduct an inspection of other products for similar nonconformities, investigate the root cause, and implement corrective and preventive actions. Additionally, investigate and report the impact on the product quality. (Article 3-2 of the GMP Ministerial Ordinance)
PMDAFY2023 · No.5Regulatory reporting and change controlRelated to pharmaceutical affairs proceduresSource file
The documents and records related to the inspected product need to be retained for the duration of the shelf life plus 30 years, in accordance with Article 30, Item 1 of the GMP Ministerial Ordinance. The Manufacturing Site specified the retention period for these documents and records as X years as a general rule. On the other hand, the retention period of temperature records was established separately. The retention period for the temperature records of the storage cabinet X was specified as X years, while the retention period for all other temperature records was uniformly specified to be X years. These records were discarded after the retention period expired. Review and revise the the written procedures to ensure that the temperature records of the inspected product are retained for the period specified in the GMP Ministerial Ordinance.
PMDAFY2023 · No.6Documentation and recordsDocument managementSource file
The document retention and management procedures required the production batch records of products for the Japanese market (records of X, X, X, and X) to be retained for the longer of the product shelf life plus 1 year or 5 years. However, the inspection found that a wide range of records had been discarded, including X records of QC, X records of X of X, and usage records of X and X. Ensure that all necessary documents and records are retained for the required period as specified in Article 20 of the GMP Ministerial Ordinance.
PMDAFY2023 · No.7Documentation and recordsDocument managementSource file
The following deficiencies were identified in the quality control activities. In addition to promptly taking measures (e.g., allocation of necessary resources), clarify the time frame for the completion of the corrective actions and develop and report risk mitigation measures to be taken during the interim period. (1) There were X cases of unperformed stability monitoring tests as of MM 20YY, making it difficult to assure the quality of the market-released products. (Violation of Article 11-2 of the GMP Ministerial Ordinance) (2) About X cases of critical deviation (e.g., use of raw materials for production before completion of acceptance test) occurred between MM and MM 20YY. No effective corrective action or preventive action had been taken despite the recurrence of deviations caused by similar factors. (Violation of Article 15 of the GMP Ministerial Ordinance)
PMDAFY2023 · No.8Deviation, CAPA, and investigationDeviation handlingSource file
Deficiencies described in (1) and (2) below were identified in relation to the handling of the event where the results of the X test for stability monitoring of X (lot number: X) at X months and X months did not conform to the approved specification of over X µg/mL (hereinafter referred to as “OOS”). Reevaluate the impact on product quality as specified in Article 11-2, Paragraph 1, Item 4 of the GMP Ministerial Ordinance. Also, take preventive measures to ensure appropriate evaluation of the impact on the product quality in future events. Furthermore, take appropriate actions for (3). (1) The impact on product quality was dismissed despite the lack of scientific evidence to deny the nonconformance of the lot to the approved specifications, as described below. (i) The initial X test at X months yielded X µg/mL. In the retest, OOS was observed in X out of 6 tests. However, it was determined that there was no quality problem based on the test result at 0 month (X µg/mL) and the test precision, concluding that no quality change had occurred since 0 months, despite the fact that conformance to the specifications had not been proven. Even if it had been determined that there had been no change in quality since 0 months, the quality at 0 months might not have conformed to the approved specifications, given that OOS was observed again in the X-month test. However, this possibility was not evaluated. (ii) Although the initial X test at X months was X µg/mL and OOS was observed in X of 6 retests, it was determined that there was no quality problem as stated in (i) above. (2) According to the report, the OOS was considered to affected only the given lot. However, the rationale for this conclusion could not be confirmed. (3) As noted in the discussion at the time of this OOS, there was a certain variation in the test results. Possible nonconformance of the product quality to the specifications cannot be ruled out even when the result is close to the lower limit of the …
PMDAFY2023 · No.9Deviation, CAPA, and investigationDeviation handlingSource file
In the deviation case (control number X), batch X of intermediate X, in which the deviation occurred, failed to meet the specifications. These specifications were defined in the drug master file (hereinafter referred to as the "MF"), which also specified the procedures for handling intermediates that did not meet the specifications. However, the intermediate was used in the next step without following the procedures specified in the MF or reevaluating the appropriateness of the acceptance criterion for X. This decision was made because the intermediate met all other specifications except for X, and it was determined that the residue of X would not affect the quality of the final drug substance given the manufacturing process. Nonconforming raw materials or intermediates must not be used. Only appropriately treated raw materials and intermediates that conform to the specifications should be used. (Article 3-2 of the GMP Ministerial Ordinance)
PMDAFY2023 · No.10Deviation, CAPA, and investigationDeviation handlingSource file
The procedures allowed for conditional release to the next manufacturing site before the release decision was made at the original manufacturing site. An actual case of conditional release was identified. Regarding the identified case, it was explained that the primary review of the manufacturing record and the review of the test record had been completed before the conditional release, that there was no deviation for which evaluation had not been completed, and that only the final review of the manufacturing record remained incomplete. Revise the procedures to ensure that release does not occur before a release decision is made according to the provisions of Article 12 of the GMP Ministerial Ordinance.
PMDAFY2023 · No.11Quality unit oversightRelease testingSource file
The serological test for the infectious pathogen described in the application for marketing authorization was performed at X, which supplies X. However, the testing methods had not been checked for discrepancies with the contents of the application for marketing authorization. Verify that there is no discrepancy with the contents of the application for marketing authorization and report the results.
PMDAFY2023 · No.12Material and supplier controlSupplier controlSource file
The manufacturing site had been outsourcing some of the testing and calibration of the manufacturing equipment and testing instruments to an external contractor after concluding an agreement. However, there were no procedures in place for managing external contractors as specified in Article 8, Paragraph 1, Item 7 of the GMP Ministerial Ordinance. Apart from the external contractor to whom the production was outsourced, the suitability and capability of external contractors had not been checked, nor had periodic verification been conducted to ensure that they were appropriately and smoothly performing the outsourced manufacturing/quality-related operations. Establish procedures to ensure the appropriate execution of the operations described in Article 11-5 of the GMP Ministerial Ordinance and perform the operations appropriately.
PMDAFY2023 · No.13Material and supplier controlSupplier controlSource file
Multiple scratches resulting from abrasion were found on the internal part of the mill. It was explained that the cause was unknown. However, there was no basis for denying that the event had occurred during the manufacturing process or after assembling the mill. This posed a risk of product contamination with foreign metal particles. No inspection equipment (e.g., a metal detector for the tableting machine) was installed at the manufacturing site. Contamination was only checked during operations and the visual inspection of tablets, and the ability to detect contamination with foreign metal particles had not been verified. In light of these observations, investigate the cause of the multiple scratches on the metal surface of the mill. Based on the investigation results, implement improvement measures to prevent the release of products contaminated with metal powder. (Article 8, Paragraph 1, Item 2 and Article 10, Item 11 of the GMP Ministerial Ordinance)
PMDAFY2023 · No.14Equipment and facilityControl of facilities and equipmentSource file
1. Sterile drugs were manufactured using the aseptic manipulation method at the manufacturing site. The aseptically filtered drug solution was filled inside the Grade-A clean booth. However, the presence or absence of contamination in the Grade-A area had not been evaluated appropriately, as shown below. Therefore, sterility assurance could not be confirmed. Perform a risk assessment for each process from the perspective of sterility assurance and take the necessary measures. (1) Environmental monitoring A. Airborne bacteria and adherent bacteria, excluding those on fingers, were evaluated based on the mean values at multiple sampling points. Therefore, even if bacteria were detected in the Grade-A area, the final result could fall below the acceptance criterion. B. A deviation case (control number X) occurred, in which the level of adherent bacteria detected on the Grade-A floor exceeded the acceptance criterion. During the deviation handling process, results from other monitoring points were unjustifiably added to the recalculation of the mean value.. It was concluded that this did not constitute a deviation because the recalculated mean level fell below the acceptance criterion. Therefore, the necessary investigation of the cause and evaluation of the impact on the product were not conducted, even though they should have been. C. While the measurement of airborne bacteria was included in the review process for release testing and product quality assessment, the measurement of adherent bacteria on operators was not considered. Therefore, even when the measurement of adherent bacteria on operators exceeded the acceptance criterion, it was not evaluated. D. The settle plate count of airborne microorganisms was not measured, nor was its appropriateness demonstrated. Since many adherent bacteria have been detected in the Grade-A area, consider implementing settle plate count measurement to evaluate the deterioration of the filling environment. (2) Bioburden control …
PMDAFY2023 · No.15Aseptic processing and sterility assuranceSterility assuranceSource file
2. As shown in 1 (1) B and 1 (4) A above, inappropriate averaging was performed in the event to be appropriately handled as an abnormality/deviation in terms of sterility assurance. The events were intentionally defined as non-deviation. No necessary investigation of the cause or evaluation of the impact on the product quality was conducted. No corrective/preventive action was taken. Check for any other events that should have been handled as deviations and appropriately handle any deviations identified as needed. Also, investigate the cause of the inappropriate handling and make improvements.
PMDAFY2023 · No.16Deviation, CAPA, and investigationDeviation handlingSource file
Products rejected for use or release were stored in the refrigerated warehouse of X as described below. However, no methods of storage and management of products rejected for use or release were specified in the written procedures nor was a management supervisor appointed. Investigate the cause of the storage of these products in the refrigerated warehouse and make appropriate improvements. Appoint a person familiar with handling of products rejected for use or release as a supervisor and specify his/her responsibilities and authorities in accordance with Article 17, Paragraph 2 of the GMP Ministerial Ordinance. Also, the supervisor should specify the handling method (e.g., separate and store the product rejected for use or release for a certain period of time and then process the product appropriately) and promptly operate the procedures. (1) Products rejected for release due to a deviation were placed on top of conformed products. The rejected products had an "UNDER TESTING" label instead of a "REJECTED" label and were not moved to the storage space for rejected products. (2) Expired products with a red tape on the outer package were stored in the warehouse. Defective products from multiple lots were stored collectively in a space separated by yellow cones and chains. However, no written procedures were available for separation and storage of rejected products. (3) While the person responsible for separation and storage of recalled products at the manufacturing site had been specified in writing, there was no document specifying a person responsible for separation and storage of rejected products in advance.
PMDAFY2023 · No.17Other quality systemRejected product controlSource file
Production of an additional lot X was started in spite of the cause of the deviation (X was out of control value) in the third lot X occurred during the manufacturing process validation of X, which is one of the drug substances used in X Injection, had not been fully investigated. Adequately investigate the cause of the deviation of X, take preventive actions, and perform PV.
PMDAFY2023 · No.18Validation and qualificationValidationsSource file
The validation method of PV of the filling process of the inspected product was as shown below. The robustness of the filling process could not be verified because the Quality of the capsules throughout the filling process was not assured. (1) Assay and elution were evaluated by sampling in the initial, middle, and last phases of the filling process after the in-process appropriateness had been verified in the PV. The entire filling process was divided into X phases. For example, the initial phase of the filling process was defined as from the start of filling to phase X. A total of X capsules was sampled during the phase, and randomly selected X capsules were used for the evaluation of the uniformity of strength. For this reason, evaluation of individual phases was not performed. The validation method did not allow for evaluation of chronological uniformity of strength in X phases. (2) The validation method in (1) was also used for the validation of prototype production before the PV. Variation in strength of the drug substance by particle size and segregation were not evaluated. It was explained that the validation method for the filling process was the same as that used by the outsourcing manufacturer. However, the validation method was not based on the data to be used as the basis (e.g., data of prototype production verified at the manufacturing site). Also, deviation cases of suspected nonuniformity of strength of the manufactured PV lot occurred as described in Other Deficiency Verify the robustness of the filling process based on the variation of strength of the drug substance by particle size and the segregation in capsules sampled in the initial to last phases. (Article 13 of the GMP Ministerial Ordinance) Also, determine the scope of commercialization based on the above validation results. Furthermore, appropriately evaluate the uniformity of the lot and determine the feasibility of distributing the lots already manufactured to the market if such …
PMDAFY2023 · No.19Validation and qualificationValidationsSource file
There were several manufacturing equipment used for the inspected product. The manufacturing process for several production scales was specified for some of the steps in the drug master file (hereinafter referred to as the “MF”). A list of manufacturing equipment used for the commercial production and the process validation (hereinafter referred to as the “PV”) was presented during the inspection. However, it was hard to properly identify which facilities had been used in which stage because some of the information was inaccurate. The plans, reports, and procedures for the PV performed at the manufacturing site in 20YY, 20YY, 20YY, and 20YY were checked. Appropriate implementation of PV could not be confirmed as described below. (Violation of Article 13, Paragraph 1, Item 1 of the GMP Ministerial Ordinance) (1) Some of the reaction vessels and centrifuges which are used for commercial production were not used in PV. No basis for constant production of products of required quality without performing PV using these facilities was presented. (2) The MF specified the manufacturing process at 3 production scales; X to X kg, X to X kg, and X to X kg; for Step X. Different reaction vessels and centrifuges were used for each of the production scales. However, PV had not been performed at the production scale of X to X kg. Also, no basis for constant production of products of required quality without performing PV using these facilities was presented. (3) The procedures for PV specified to start commercial production after PV. As described in (1) and (2) above, however, commercial production was performed by using some of the facilities at some of the production scales without following the procedures for PV. In light of the above, take the following measures for this case. According to the explanation of the manufacturing site, the product manufactured for the Japanese market has not been released to date. Do not release products manufactured for the Japanese market until …
PMDAFY2023 · No.20Validation and qualificationValidationsSource file
During the acceptance of the drug substance, the manufacturing site only checked the COA issued by the manufacturing site of the drug substance for each lot and did not judge whether it was acceptable or not. No visual inspection or identification test was performed under the responsibility of the manufacturing site. Perform acceptance tests for each lot of the drug substance in accordance with Article 11, Paragraph 1, Item 4 of the GMP Ministerial Ordinance and prepare and retain the records. When checking the COA issued by the manufacturing site of the drug substance in place of an acceptance test of the drug substance, clarify the reasonable grounds to show that there is no impact on the quality and check the authenticity of the drug substance accepted by performing a visual inspection or identification at the manufacturing site.
PMDAFY2023 · No.21Laboratory and QC controlsTest records, test proceduresSource file
The following deficiencies were found in the test X of Injection X. Perform appropriate verification and evaluation of each deficiency and report the results. (1) X analyses of a single sample were performed under the repeatability conditions each at the inspected site and the transferring company for the technology transfer of test X. The relative standard deviation calculated for the combined data from X analyses was within the acceptance criterion of X%. However, since the acceptance criterion of X% was the intermediate precision confirmed during the validation of analytical procedures at the transferring company, this criterion was not appropriate as an evaluation criterion for the protocol of the test designed for the technology transfer. The relative standard deviation of the analytical results produced at the inspected site and the transferring company was X% and X%, respectively. The upper limit of the 95% confidence interval was X% and X%, respectively, showing a large gap. However, the appropriateness was not explained clearly. (Article 13 of the GMP Ministerial Ordinance) (2) OOS frequently occurred during the stability monitoring of the PV lots. For example, the release test of the first PV lot of dose X performed on DD MM, 20YY was X%, which was conforming. However, the stability monitoring at X months and X months showed OOS: X% and X%, respectively. The stability monitoring at X months found nonconformance to SST. Since no clear cause was known, a X-month stability monitoring was performed after making several improvements based on the information provided by the transferring company of the test on MM 20YY. The result was conforming (X%). According to the inspected site, the system suitability was verified with the improved testing procedures. However, appropriateness of the analytical performance had not been verified nor had the validity of the data from the release test and the stability monitoring performed using the pre-modification testing …
PMDAFY2023 · No.22Laboratory and QC controlsHandling of laboratory abnormalities, OOS, and OOTSource file
In the OOS case (Report No. X) occurred in MM 20YY, X-percent peaks were noted immediately after the main peak of the test X at X months of the product stability monitoring. The peaks were considered to be associated with the major component partially separated and eluted at different positions due to the column condition (hereinafter referred to as the "separated peaks"). In the OOS investigation, the conventional analytical column (X, X μm) (hereinafter referred to as the "conventional column") and the analytical column of another manufacturer (X, X μm) (hereinafter referred to as the "new column") were both analyzed. The new column was used for the test in place of the conventional column since the analysis found no separated peak in the new column. However, change management was not performed for the change of column. The following deficiencies were found in the actions taken after the OOS investigation. As a result, the data from the test may not be guaranteed. (1) Although following transitions associated with the change of column were noted, no validation of analytical procedures was performed. The validation characteristics such as specificity, accuracy, precision, quantitation limit, and detection limit were not verified. (i) The elution pattern of blank peaks of impurity changed, and the elution positions of X, X, X, and X analyzed in the system suitability test also changed. (ii) The elution position of the blank peak before the main peak moved to after the peak of RRT X, possibly overlapping with the impurity peak in this region. The impurity eluted at this position was not analyzed because the procedures did not include calculation of strength of the related substance by subtracting the blank peak. Even if subtraction is performed, whether the related substance of X-percent level can be quantified with appropriate accuracy and precision is unknown. (iii) For example, the retention time of X was changed from X minutes to X minutes. However, the area …
PMDAFY2023 · No.23Laboratory and QC controlsHandling of laboratory abnormalities, OOS, and OOTSource file
The following deficiencies were found in the quantitative assay directions/records for the PV of product X on the personal desk of the person who performed the test. A. Issuance and management of the forms for testing directions/records (1) According to the procedures, the forms for testing directions/records for PV and for some other testing directions/records (e.g., solution preparation process) are printed by the person who performed the test and signed by the person responsible for testing before issuance/provision. However, the quantitative assay testing directions/records were not signed by the person responsible for testing. The assay was performed before the directions had been provided. (2) Events similar to the above had been noted. The recurrence occurred although at least 2 events had been handled as deviations, and corrective actions had been taken. (3) The interview of the person who performed the test found there had been similar cases for which no deviation handling was performed. In one of the cases, the test was performed without directions. The person responsible for testing backdated, signed, and issued the testing directions/records after the test was completed. B. Contents of records (1) It was explained that preparation using the reference standard had not been started. However, the control number of the reference standard to be provided at the time of use had been provided in advance. (2) Whether the solution X for quantification had been prepared according to the directions could not be determined based on the record. Although the person who performed the test was aware of the inappropriateness of the information in the section of the preparation record, the information was not corrected nor was the necessary record appropriately provided. (3) Two sets of testing directions/records seemed to have been prepared on the same day. However, no clear explanation was given to the second set of the preparation record. (4) The receipt issued after …
PMDAFY2023 · No.24Data integrityDI-relatedSource file
The stability monitoring violated the requirements in Article 11-2, Paragraph 2 of the GMP Ministerial Ordinance as follows: As shown in Other Deficiency 12, the appropriateness of judging the conformance based on the retest results after OOS results had been shown in the stability monitoring was unclear. As shown in Other Deficiency 1 (2) and 14, no necessary actions were taken when a decreasing trend indicating possible OOS was noted in the results of product stability monitoring. Based on the above, possible distribution of OOS products before the expiration date in the market could not be ruled out. Take the following actions for all the products subject to inspection including product X. (1) Check the appropriateness of the reported value in the stability monitoring and report the results. If an OOS result is obtained or the reanalysis results are used as the reported values, include the appropriateness of OOS handling, the reason for and the appropriateness of the reanalysis, and the pre-analysis results in the report. (2) Perform a trend analysis on the results of the stability monitoring and, if necessary, additional testing to check for potential OOS before the expiration date. If there is a risk of OOS, take appropriate actions including contacting the marketing authorization holder. (3) Evaluate the appropriateness of the shelf life established based on the results of the actions described in (1) and (2) above and the quality of all lots manufactured, improve the manufacturing control, review the specifications for the raw materials and the intermediates, and consider the need for process revalidation.
PMDAFY2023 · No.25Stability and storageStability monitoringSource file
The critical raw materials and packaging/labeling materials to be kept as reference samples were not evaluated. These reference samples were not kept. Evaluate the risk of the raw materials and the packaging/labeling materials affecting the product quality and keep their reference samples in amounts of at least twice the quantity necessary for the prescribed testing on each batch of such raw materials and in amounts of the quantity necessary for the prescribed testing on each lot of such packaging/labeling materials, under suitable storage conditions for two years from the date of release certification of the product batch.(Article 11, Paragraph 1, Item 6 of the GMP Ministerial Ordinance)
PMDAFY2023 · No.26Laboratory and QC controlsReserve samples/retention samplesSource file
No deficiencies match.
Firm names are removed in the original and figures and lots are masked with ●. Years are Japanese fiscal years (starting in April).
Not translated. Long sentences are shortened and link to the source file. As of 2026-11-10.